IMPROVING CARE THROUGH EDUCATION, ADVOCACY, QUALITY OF LIFE AND BEYOND

CARO 2017
ANNUAL SCIENTIFIC MEETING

Hilton Toronto Hotel
TORONTO, ON • September 13–16
THANK YOU

THANK YOU TO OUR SPONSORS GENEROUS SUPPORT.

SPONSORS

PLATINUM
   Elekta
   Varian Medical Systems

BRONZE
   AbbVie
   Astellas Pharma Canada
   Hoffman-La Roche Ltd.
   Sanofi

SUPPORTERS
   Bayer
   Ferring Pharmaceuticals
   TerSera Therapeutics

EXHIBITORS
   Accuray
   Augmenix
   Best Medical Canada
   Canadian Association of Medical Radiation Technologists
   Central Care, PA
   College of Medical Radiation Technologists of Ontario
   Donaldson Marphil Medical Inc
   HSC Medical Inc
   IBA Dosimetry
   IsoAid
   MIM Software Inc
   Mölnlycke Health Care
   Orfit Industries America
   Philips Healthcare
   ViewRay, Inc.
   Zeiss Canada
**Board of Directors 2015–17**
- Eric Vigneault, President
- Michael Brundage, President-Elect
- Jacqueline Spayne, Secretary-Treasurer
- Ross Halperin, Past President
- Amanda Caissie
- Guila Delouya
- Zsolt Gabos
- Jacqueline Lam
- Gerard Morton
- David Petrik
- George Rodrigues
- Isabelle Roy

**ASM Organizing Committee**
- Fabio Cury, ASM Chair
- Amanda Caissie, Awards
- Jennifer Croke
- Marc Gaudet
- Meredith Giuliani
- Mary Hooey, ASM Coordinator
- Paris-Ann Ingledew
- Irene Karam
- Jacqueline Lam
- Brian Liszewski
- Kim O’Hearn, ASM Recorder
- Ericka Wiebe

**Guest Faculty**
- CARO Lecturer
  - Claire Snyder
- Gordon Richards Lecturer
  - Michael Brundage
- Jean Roy Lecturer
  - Gerard Morton
- Closing Keynote
  - Shelly Dev
- Theme Symposium Speakers
  - Joanne Alfieri
  - Brock Debenham
  - Meredith Giuliani
  - Sue Glover Takahashi
  - Paris-Ann Ingledew
  - Barbara-Ann Millar
  - Theresa Trotter

**CARO 2017 Learning Objectives**

The theme of the meeting is *Improving Care through Education, Advocacy, Quality of Life and Beyond.*

**Overall Conference Objectives**

At the end of this conference, the attendees will be able to:

- Demonstrate an understanding of the Royal College of Physicians and Surgeons of Canada Competence by Design Program on Radiation Oncology Residency Training and Continuing Education.
- Discuss the aspects that influence the human factors associated with patient care, including, but not limited to professional training and maintenance of skills, and life beyond profession;
- Demonstrate an understanding of current quality Canadian-initiated research in Radiation Oncology;
- Understand the importance of the inter-professional collaboration (radiation oncology, medical physics, and radiation therapy) in achieving these goals.

**Accreditation**

- This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the University of Toronto Office of Continuing Professional Development. Participants can claim up to a maximum 17.5 Category 1 Credits and American Medical Association – 17.5 Category 1 Credits
- Canadian Association of Medical Radiation Technologists (CAMRT) up to 24.5 Category Credits – RCEEM Reference Number: CARO-2017-147
- Medical Dosimetrist Certification Board (MDCB) – 5 CE Credits

**Presentations**

All oral presentations in this program contain 25% for interactivity.
- 90-minute presentations include 60-minute talk, 30-minute question and answer period.
- 60-minute presentations include 45-minute talk, 15-minute question and answer period.
- 10-minute presentations include 7-minute talk, 3-minute question and answer period.
As a rule, the first author is the presenting author unless indicated by an asterisk (*).
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>LETTER FROM CARO PRESIDENT</td>
<td>2</td>
</tr>
<tr>
<td>LETTER FROM CHAIR, ASM COMMITTEE</td>
<td>4</td>
</tr>
<tr>
<td>WEDNESDAY, September 13, 2017</td>
<td>7</td>
</tr>
<tr>
<td>PRECONFERENCE</td>
<td>7</td>
</tr>
<tr>
<td>THURSDAY, September 14, 2017</td>
<td>8</td>
</tr>
<tr>
<td>THEME SYMPOSIUM</td>
<td>8</td>
</tr>
<tr>
<td>CARO LECTURE</td>
<td>8</td>
</tr>
<tr>
<td>ORAL SESSION 1 – BREAST CANCER (Abstract #1–6)</td>
<td>8</td>
</tr>
<tr>
<td>ORAL SESSION 2 – PALLIATIVE CARE (Abstract #7–12)</td>
<td>9</td>
</tr>
<tr>
<td>POSTER DISCUSSION SESSION 1 (Abstract #13–22)</td>
<td>10</td>
</tr>
<tr>
<td>POSTER DISCUSSION SESSION 2 (Abstract #23–32)</td>
<td>11</td>
</tr>
<tr>
<td>FELLOW COMPETITION (Abstract #33–38)</td>
<td>12</td>
</tr>
<tr>
<td>ANNUAL GENERAL MEETING</td>
<td>12</td>
</tr>
<tr>
<td>POSTER VIEWING AND WELCOME RECEPTION</td>
<td>12</td>
</tr>
<tr>
<td>FRIDAY, September 15, 2017</td>
<td>13</td>
</tr>
<tr>
<td>GORDON RICHARDS LECTURE</td>
<td>13</td>
</tr>
<tr>
<td>RESIDENT COMPETITION (Abstract #39–44)</td>
<td>13</td>
</tr>
<tr>
<td>ORAL SESSION 3 – LUNG CANCER (Abstract #45–50)</td>
<td>14</td>
</tr>
<tr>
<td>ORAL SESSION 4 – GENITOURINARY CANCER, RADIATION TREATMENT DELIVERY (Abstract #51–56)</td>
<td>14</td>
</tr>
<tr>
<td>ORAL SESSION – CANADIAN BRACHYTHERAPY GROUP (Abstract #57–62)</td>
<td>15</td>
</tr>
<tr>
<td>ORAL SESSION 5 – RADIATION TREATMENT, RADIOSURGERY (Abstract #63–68)</td>
<td>16</td>
</tr>
<tr>
<td>ORAL SESSION 6 – GYNECOLOGIC CANCER (Abstract #69–74)</td>
<td>16</td>
</tr>
<tr>
<td>WORKSHOP 1</td>
<td>17</td>
</tr>
<tr>
<td>WORKSHOP 2</td>
<td>17</td>
</tr>
<tr>
<td>WORKSHOP 3</td>
<td>17</td>
</tr>
<tr>
<td>DINNER AND AWARDS - THE RED CARPET AFFAIR</td>
<td>17</td>
</tr>
<tr>
<td>SATURDAY, September 16, 2017</td>
<td>18</td>
</tr>
<tr>
<td>DR PAMELA CATTON MEMORIAL FUN RUN/WALK</td>
<td>18</td>
</tr>
<tr>
<td>JEAN ROY LECTURE</td>
<td>18</td>
</tr>
<tr>
<td>ORAL SESSION 7 – HEAD AND NECK CANCER (Abstract #75–80)</td>
<td>18</td>
</tr>
<tr>
<td>ORAL SESSION 8 – CNS, EXPERIMENTAL THERAPEUTICS (Abstract #81–86)</td>
<td>19</td>
</tr>
<tr>
<td>WORKSHOP 4</td>
<td>19</td>
</tr>
<tr>
<td>WORKSHOP 5</td>
<td>19</td>
</tr>
<tr>
<td>WORKSHOP 6</td>
<td>20</td>
</tr>
<tr>
<td>REVIEWERS’ CHOICE (Abstract #87–82)</td>
<td>20</td>
</tr>
<tr>
<td>KEYNOTE</td>
<td>21</td>
</tr>
<tr>
<td>POSTER ABSTRACTS</td>
<td>22</td>
</tr>
<tr>
<td>LOCAL AREA MAP AND CROF RUN/WALK</td>
<td>33</td>
</tr>
</tbody>
</table>
Dear Colleagues,

Canada celebrates its 150th anniversary this year, and Toronto is hosting the 2017 CARO ASM! This year’s theme is Improving Care Through Education, Advocacy, Quality of Life and Beyond.

Our overall objectives are to demonstrate an understanding of the Royal College of Physicians and Surgeons of Canada’s Competence by Design program on radiation oncology residency training and continuing education; discuss the aspects that influence human factors associated with patient care, including, but not limited to, professional training and maintenance of skills, and life beyond profession; demonstrate an understanding of current quality Canadian-initiated research in radiation oncology and understand the importance of interprofessional collaboration (radiation oncology, medical physics and radiation therapy) in achieving these goals.

The vibrant CARO community has once again contributed scientific content with over 92 oral presentations and 149 poster presentations, along with a wide variety of workshops and the theme symposium Coming Soon! Competence by Design – What You Need to Know.

We begin on Thursday morning with the CARO Lecturer, Claire Snyder from Baltimore, who will speak about Unlocking the Potential of Patient-Reported Outcomes. The highlights of the day on Friday are the Gordon Richards Lecturer, Michael Brundage from Kingston, who will present Advocating for Quality… and the Jean Roy Memorial Lecturer, Gerard Morton from Toronto, who will discuss Brachytherapy Education in an Era of High Technology.

Our social events include the Welcome Reception at the hotel on Thursday evening and the Dinner and Awards Ceremony at One King West, Grand Banking Hall on Friday night! Both events will provide quality networking time with your friends and colleagues. If you did not purchase your ticket for the dinner and you would like to attend, please visit the registration desk.

Don’t forget to bring your sneakers for the annual fundraising event for CROF, the Dr. Pamela Catton Memorial Fun Run/Walk on Saturday morning (not too early!). Please join us for a 5 km run or 2.5 km walk, or just come to cheer on your colleagues. Once again, Photon Man and Gamma Gal will be ready to go! If you are not participating this year, please support your colleagues with a generous donation to CROF!

Finally, I would like to thank the ASM Committee: Fabio Cury—ASM Chair; Mary Hooey—ASM Coordinator, Amanda Caisse, Jennifer Croke, Marc Gaudet, Irene Karam, Brian Liszewski, Meredith Giuliani, Paris-Ann Ingledew, Jacqueline Lam, Kim O’Hearn, Ericka Weibe and all the staff at Secretariat Central.

Welcome and enjoy your time in Toronto, a city with plenty of diversity, culture, cuisines, and so much more!

Sincerely,

Eric Vigneault, MD FRCPC
President, CARO
Cette année, le Canada célèbre son 150e anniversaire et Toronto accueille la RSA 2017 de l’ACRO! Le thème de cette année est « Améliorer les soins au moyen de l’éducation, de la défense des droits, de la qualité de vie et autres ».

Nos objectifs globaux consistent à comprendre l’impact du programme « La compétence par conception » du Collège royal des médecins et chirurgiens du Canada sur la formation des résidents en radio-oncologie et sur la formation continue; discuter des aspects qui influencent les facteurs humains associés aux soins prodigués aux patients, y compris, mais sans s’y limiter, la formation professionnelle et le maintien des compétences, et la vie au-delà de la profession; comprendre la recherche de haute qualité actuellement en cours au Canada en matière de radio-oncologie et l’importance de la collaboration interprofessionnelle (la radio-oncologie, la physique médicale et la radiothérapie) pour atteindre ces objectifs.

La communauté dynamique de l’ACRO a une fois de plus élaboré un programme scientifique qui comprend plus de 92 présentations orales et 149 présentations par affiche, ainsi qu’un vaste éventail d’ateliers et un symposium thématique intitulé Coming Soon! Competence by Design – What You Need to Know (en anglais seulement).

Nous débuterons le jeudi matin avec la conférencière de l’ACRO, Claire Snyder de Baltimore, qui abordera le sujet suivant : Unlocking the Potential of Patient-Reported Outcomes (en anglais seulement). Les activités principales le vendredi comprendront la conférence Gordon Richards, qui sera donnée par Michael Brundage de Kingston sur le sujet Advocating for Quality… et la conférence Jean Roy, qui sera donnée par Gerard Morton de Toronto sur le sujet Brachytherapy Education in an Era of High Technology (en anglais seulement).

Nos activités sociales comprendront la réception d’accueil à l’hôtel le jeudi soir ainsi que le souper et la cérémonie de remise de prix à One King West, Grand Banking Hall le vendredi soir! Les deux activités offriront des opportunités de réseautage de qualité pour vous et vos collègues. Si vous n’avez pas acheté de billet pour le souper et que vous souhaiteriez participer à l’événement, adressez-vous au bureau d’inscription.

N’oubliez pas d’apporter vos chaussures de course à l’événement annuel de collecte de fonds pour la FCRO, la course/marche amicale commémorative Dre Pamela Catton le samedi matin (pas trop tôt!). Veuillez vous joindre à nous pour une course de 5 km ou une marche de 2,5 km, ou venez tout simplement pour supporter vos collègues. Encore une fois, Photon Man et Gamma Gal seront prêts pour l’événement. Si vous ne participez pas cette année, veuillez soutenir vos collègues en faisant un don généreux à la FCRO!


Bienvenue et profitez de votre séjour à Toronto, une ville pleine de diversité, de culture, de gastronomie et beaucoup plus encore!

Cordialement,

Eric Vigneault, MD FRCPC
Président de l’ACRO
Dear Colleagues,

The CARO Annual Scientific Meeting (ASM) is finally back in Toronto! It’s been almost 10 years since CARO last held a meeting here, so this visit is long overdue. Several scientific and technological advances have been made in radiation oncology, which have been discussed in depth at previous meetings, so we felt that this year’s meeting should examine the human factors linked to the advances of our specialty, including medical education, maintenance and development of knowledge and skills, and personal and professional quality of life. This focus was not chosen randomly – the Royal College of Physicians and Surgeons of Canada is currently implementing an initiative known as Competence by Design to improve training and continuing professional development for physicians. With this in mind, the ASM Committee organized this year’s meeting around the theme Improving Care Through Education, Advocacy, Quality of Life and Beyond.

Coincidentally (or not), this year’s meeting will happen at the same time as the Toronto International Film Festival (TIFF). Both events feature high-profile stars, special presentations and awards. Our scientific lineup includes oral and poster presentations, workshops and a variety of internationally renowned speakers, while our social program brings together new and old friends at an exciting Red Carpet Affair as well as other not-so-formal events.

The traditional Resident Refresher Course will start on Wednesday, covering brachytherapy and plan reviewing. A parallel session for radiation oncologists will review current and evolving trends in radiation oncology. At the end of the day, both groups will come together for a provocative joint session on Challenging Cases in IGRT and How to Solve Them. This year’s theme symposium will bring together several experts in medical education who are deeply involved with the Competence by Design initiative to demonstrate the changes and challenges associated with competency-based medical education in radiation oncology. The ASM will end with the top-scoring peer-reviewed oral presentations at the Reviewers’ Choice session and Resident and Fellow Competitions. The workshops this year are offered on two days, which will provide more opportunities for participants to delve into different subjects in a friendly format. New this year, we will have a closing keynote presentation by Dr. Shelly Dev, exploring what is beyond our professional lives.

Our “starring” lectures this year will be given by Professor Claire Snyder, Dr. Michael Brundage and Dr. Gerard Morton, who will continue to explore questions associated with the human factor that can impact patient care and outcomes.

The Dr. Pamela Catton Memorial Fun Run/Walk for CROF will allow participants to recharge their batteries on Saturday morning in support of the Canadian Radiation Oncology Foundation. Run! Walk! Pledge!

I look forward to seeing you in Toronto for another “award-winning” scientific meeting, complete with practice-changing information and wonderful social activities.

Sincerely,

Fabio Cury, MD FRCPC
Chair, ASM Committee
Chers collègues,

La Réunion scientifique annuelle (RSA) de l’ACRO est finalement de retour à Toronto! Cela fait maintenant presque dix ans que l’ACRO a tenu sa réunion ici; cette visite était donc attendue depuis longtemps. De nombreuses percées scientifiques et technologiques ont été réalisées en radio-oncologie, et elles ont été analysées en profondeur lors des réunions précédentes. Par conséquent, nous estimons que la réunion de cette année devrait aborder les facteurs humains liés à ces percées dans notre spécialité, notamment la formation médicale, le maintien et le développement des compétences et des connaissances, et la qualité de vie professionnelle et personnelle. Ce point de mire n’a pas été choisi au hasard : le Collège royal des médecins et chirurgiens du Canada a récemment mis en place une initiative appelée « La compétence par conception », afin d’améliorer la formation et le perfectionnement professionnel continu des médecins. Ainsi, le comité de la RSA a organisé la réunion de cette année sous le thème de « Améliorer les soins au moyen de l’éducation, de la défense des droits, de la qualité de vie et autres ».

Par coïncidence (ou peut-être pas), la réunion de cette année aura lieu en même temps que le Festival international du film de Toronto (TIFF). Les deux événements comporteront des vedettes de haut niveau, des présentations spéciales et des prix. Notre volet scientifique comprendra des présentations orales et par affiches, des ateliers et de nombreux conférenciers reconnus à l’échelle internationale, tandis que le volet social rassemblera de nouveaux amis et d’anciens amis lors du Gala Tapis rouge tant attendu et lors d’autres événements ayant un caractère un peu mois officiel.

Le traditionnel Cours de recyclage des résidents commencera le mercredi et abordera la curiethérapie et l’examen de plans. Une séance parallèle destinée aux radio-oncologues examinera les tendances actuelles et évolutives dans la radio-oncologie. À la fin de la journée, les deux groupes se réuniront pour participer à une séance conjointe provocante sous le thème « Cas difficiles en radiothérapie guidée par l’image et comment les résoudre ». Le symposium thématique de cette année réunira de nombreux experts en formation médicale qui sont profondément engagés dans l’initiative « La compétence par conception » pour démontrer les changements et les défis associés à la formation médicale fondée sur les compétences en radio oncologie. La RSA se terminera par les présentations orales examinées par les pairs ayant reçues le meilleur pointage lors de la séance « Choix de l'examineur » et des concours destinés aux résidents et aux boursiers. Les ateliers de cette année sont offerts sur deux jours, ce qui fournira aux participants davantage de possibilités d’aborder les différents sujets de façon plus approfondie dans un cadre amical. À titre de nouveauté cette année, nous aurons une conférence de clôture par la Dr Shelly Dev, abordant les aspects allant au-delà de nos vies professionnelles.

Cette année, nos conférences « vedettes » seront données par la professeure Claire Snyder, le Dr Michael Brundage et le Dr Gerard Morton, qui continueront à aborder les questions liées au facteur humain qui peuvent influencer les soins prodigués aux patients et les résultats.

La course/marche amicale commémorative Dre Pamela Catton permettra aux participants de refaire le plein d’énergie le samedi matin en appui à la Fondation canadienne de radio-oncologie (FCRO). Courez! Marchez! Donnez!

J’espère avoir la chance de vous croiser à Toronto pour une autre réunion scientifique « primée », remplie de renseignements qui changeront la pratique et de merveilleuses activités sociales.

Cordialement,

Fabio Cury, MD FRCPC
Président du comité de la RSA
CARO 2017 • IMPROVING CARE THROUGH EDUCATION, ADVOCACY, QUALITY OF LIFE AND BEYOND

WEDNESDAY SEPTEMBER 13, 2017

PRECONFERENCE
7:15–8:00  REGISTRATION AND BREAKFAST  Convention Level

RESIDENT REFRESHER COURSE  Toronto I
8:00–4:00  Facilitator: Meredith Giuliani

OBJECTIVES: Upon completion of this refresher course, attendees should be able to:
1. Give an evidence-based overview of the indications for brachytherapy for prostate, cervix, lung and esophageal cancers.
2. Review the normal tissue tolerances, and acute and late side effects associated with various brachytherapy techniques.
3. Explore emerging frontiers for the use of brachytherapy in cancer care.
4. Develop skills in IMRT plan review and solving challenging image-guidance problems in clinical practice.

8:00–8:10  WELCOME AND INTRODUCTIONS  Meredith Giuliani
8:15–9:15  LDR PROSTATE BRACHYTHERAPY  Mira Keyes
9:15–10:15  HDR BRACHYTHERAPY  Gerard Morton
10:15–10:30  Break
10:30–11:30  CERVIX BRACHYTHERAPY  Israel Fortin
11:30–12:30  HDR LUNG AND ESOPHAGEAL BRACHYTHERAPY  Ranjun Sur
12:30–1:30  Lunch
1:30–2:30  PLAN LITERACY AND PRINCIPLES OF REVIEWING RT PLANS  John Kim
2:30–4:00  CHALLENGING IGRT CASES AND HOW TO SOLVE THEM  Douglas Moseley, James Loudon
5:00  Resident Social  The Merchant, 181 University Avenue

EVOLVING TRENDS IN CANADIAN RADIATION ONCOLOGY  Toronto II
9:30–4:00  Facilitator: Jennifer Croke

OBJECTIVES: For radiation oncologists to update and refresh their knowledge or skills in site-specific topics, particularly with Canadian content. It is important for maintenance of continuing education and lifelong learning. At the end of this session, participants will have reviewed:
1. Current treatment techniques and planning, including contouring, specific margins, standard doses and fractionation.
2. Latest in clinical trials.
3. Effects of the combination of radiation therapy and new immunotherapy agents.
4. Tips and tricks on how to solve challenging cases in IGRT.

9:30–9:40  WELCOME AND INTRODUCTIONS  Jennifer Croke
9:40–10:10  THE LATEST IN THE MANAGEMENT OF BRAIN METASTASES AND TECHNICAL CONSIDERATIONS  Arjun Sahgal, Mark Rushin
10:10–11:00  Break
11:00–11:30  SABR – THE FUTURE OF PROSTATE CARE  Andrew Loblaw
11:30–12:00  TEACHING AN OLD DOG NEW TRICKS: HOW SHOULD RADIOTHERAPY BE COMBINED WITH IMMUNOTHERAPY DRUGS?  Scott Bratman
12:00–12:30  SBRT  Laura Dawson
12:30–1:30  Lunch
1:30–2:00  SARCOMA  Peter Chung
2:00–2:30  Break (after break move to Toronto I)
2:30–4:00  CHALLENGING IGRT CASES AND HOW TO SOLVE THEM  Douglas Moseley, James Loudon
6:00–9:00  CARO BOARD MEETING  Governor General, 2nd floor
THURSDAY SEPTEMBER 14, 2017

7:00–8:00  MEET AND GREET (by invitation)  Governor General
REGISTRATION AND BREAKFAST  Convention Level

8:00–8:15  WELCOME AND INTRODUCTIONS – Fabio Cury, Eric Vigneault  Toronto I/II

8:15–10:15  THEME SYMPOSIUM  Moderator: Meredith Giuliani
Coming Soon! Competence by Design – What You Need to Know

OBJECTIVES: At the end of this session, the participants will be able to:

| Demonstrate an understanding of the context and rationale for competency based medical education (CBME). |
| Introduce what has been done in Radiation Oncology for Competence By Design (CBD). |
| Identify opportunities and challenges related to the implementation of CBD. |
| Identify assessment strategies in competency-based education. |
| Explore strategies to facilitate training in the CBD era. |

8:15-8:30  WELCOME AND OVERVIEW OF CBME  Meredith Giuliani
8:30-9:00  WHAT HAS BEEN DONE IN RADIATION ONCOLOGY  Theresa Trotter, Barbara-Ann Millar
9:00-9:20  OPPORTUNITIES AND CHALLENGES  Brock Debenham
9:20-10:00  PANEL AND STRATEGIES ON IMPLEMENTING COMPETENCE BY DESIGN  Joanne Alfieri, Adelle Atkinson, Sue Glover Takahashi, Paris-Ann Ingledew
10:00-10:15  CLOSE AND NEXT STEPS  Meredith Giuliani, Barbara-Ann Millar
10:15–10:45  Break

10:45–11:45  CARO LECTURE  Introduction: Eric Vigneault
Unlocking the Potential of Patient-Reported Outcomes
Claire Snyder

OBJECTIVES: At the end of this session, the participants will be able to discuss the important, and somewhat unrealized, potential of patient-reported outcomes to improve the quality of cancer care at multiple levels, including at the patient-clinician interface, in clinical research, and for performance improvement.

11:45–1:45  Lunch Break

COMMITTEE MEETINGS  Please refer to the Committee Meetings Schedule for exact times

1:45-2:45  ORAL SESSION 1 – BREAST CANCER  Toronto I
Moderators: Sarah Hamilton, Alan Nicol

OBJECTIVES: At the end of this session, the participants will be able to:

| Recognize important aspects of treatment planning and delivery for breast cancer. |
| Review current practices and outcomes of radiation therapy for breast tumours |

1  HEMATOPOETIC STEM CELL AND INFLAMMATORY CYTOKINE LEVELS ARE ASSOCIATED WITH FATIGUE AND INSOMNIA IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT RADIATION THERAPY
Fei-Fei Liu, Willa Shi, Megan McCusker, Justin Williams, J (Susie) Su, Tara Spence, Madeline Li, Wei Xu, Laleh S Ghoraie, Kathy Han, Scott Bratman, Kenneth Yip; Princess Margaret Cancer Centre, Toronto, ON

2  LONG-TERM OUTCOMES OF MICROINVASIVE BREAST CANCER IN THE CANADIAN HYPOFRACTIONATION TRIAL
Mira Goldberg¹, Sameer Parpia², Eileen Rakovitch², Laval Grimard³, Julie Bowen⁴, Himanshu Lukka⁵, Francisco Perera⁶, Anthony Fyles⁷, Timothy Whelan⁸; ¹Juravinski Cancer Centre, Hamilton, ON; ²McMaster University, Hamilton, ON; ³Odette Cancer Centre, Toronto, ON; ⁴University of Ottawa, Ottawa, ON; ⁵Northeastern Ontario Regional Cancer Centre, Sudbury, ON; ⁶London Health Sciences Centre, London, ON
3 SIMPLE IMPLEMENTATION OF A DBH TANGENTIAL IMRT TECHNIQUE FOR LEFT-SIDED BREAST CANCER
Dominique Mathieu, Nicolas Côté, Andrée-Anne Bernard, Noémie Lahaie, Stéphane Bedwani, Jean-François Aubry, David Roberge, Sophie Lavertu, Pierre Rousseau, Toni Vu; Université de Montréal, Montréal, QC

4 ELEKTA FELLOWSHIP RADIATION THERAPY PRESCRIBING PATTERNS ACROSS 6 BREAST CANCER SCENARIOS
Theodora A Kouli1, Caroline Speers2, Jeremy Hamm3, Alexa Dang1, Josh Power1, Alan Nicho1, Scott Tyldesley2, Robert Olson2; 1British Columbia Cancer Agency, Prince George, BC; 2British Columbia Cancer Agency, Vancouver, BC

5 ARE WE MISSING THE POST-OPERATIVE CAVITY IN WHOLE BREAST RADIOThERAPY? Grace Lee1, Felix Tsui1, Anne Koch1, Anthony Fyles1, Robert Dinniwell2; 1Princess Margaret Cancer Centre, Toronto, ON; 2University of Western Ontario, London, ON

6 SECOND CONSERVATIVE TREATMENT FOR BREAST CANCER LOCAL RECURRENCE USING HDR INTERSTITIAL BRACHYTHERAPY: COSMETIC OUTCOME AND QUALITY OF LIFE Marjory Jolicoeur1, Aly-Thiéman Diakité2, Talar Derashodian3, Maryse Mondat4; 1Hopital Charles LeMoyne CICM, Montréal, QC; 2University of Sherbrooke, Longueuil, QC

ORAL SESSION 2 – PALLIATIVE CARE Toronto II
Moderators: Rashid Dar, Ericka Wiebe

OBJECTIVES: At the end of this session, the participants will be able to describe several important aspects involved in the decision-making process by radiation oncologists treating patients in need for palliative treatment.

7 PALLIATIVE Thoracic RADIOTHERAPY IN ASYMPTOMATIC CENTRALLY LOCATED NON SMALL CELL LUNG CANCER (NSCLC) – TO TREAT OR TO DEFER Anil Tibdewal1, Andrea Bezjak1, Lisa Le1, Kathy Pope2, Sarika Gill1, Joseph Nachman2, Andrew Hope1, Laura Dawson1, Rebecca Wong1; 1Princess Margaret Cancer Centre, Toronto, ON; 2Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

8 ASSESSING THE UTILITY OF A PROGNOSTICATION MODEL TO PREDICT 1-YEAR MORTALITY IN PATIENTS RECEIVING RADIATION THERAPY FOR SPINAL METASTASES Dina Shi1, Yu-Hui Chen2, Tai Chung Lam3, Dana Leonard2, Andrew Schoenfeld2, Tracy Balboni1, Sonia Skamene2, John Chi3, Marco Ferrone4, Charles Cho5, Mitchell Harris6, Lauren Hertan1; 1Harvard Medical School, Boston, MA; 2Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA; 3The University of Hong Kong, Hong Kong

9 BARRIERS TO REFERRAL FOR PALLIATIVE RADIOTHERAPY: A SYSTEMATIC REVIEW Jonathan Klein1, Jonathan Livergan2; 1University of Toronto, Toronto, ON; 2British Columbia Cancer Agency, Victoria, BC

10 BEHAVIOURAL DETERMINANTS OF CANADIAN RADIATION ONCOLOGISTS’ USE OF SINGLE FRACTION PALLIATIVE RADIATION THERAPY FOR UNCOMPPLICATED BONE METASTASES Kristopher Dennis1, Janet Squires1, Sarah Asad2, Kristin Dorrance3, Alysa Fairchild4, Edward Chow4, Rebecca Wong4, Ian Graham4, Jeremy Grimshaw4; 1University of Ottawa, Ottawa, ON; 2Ottawa Hospital Research Institute, Ottawa, ON; 3University of Alberta, Edmonton, AB; 4University of Toronto, Toronto, ON

11 ASSESSING THE UTILITY OF THE SPINAL INSTABILITY IN NEOPLASIA (SINS) SCORE TO PREDICT FRACTURE AFTER CONVENTIONAL RADIATION THERAPY (RT) FOR SPINAL METASTASES Diana Shi1, Lauren Hertan2, Tai Chung Lam3, Sonia Skamene2, John Chi3, Charles Cho4, Marco Ferrone4, Mitchell Harris5, Yu-Hui Chen6, Tracy Balboni1; 1Harvard Medical School, Boston, MA; 2Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA; 3The University of Hong Kong, Hong Kong

12 ARE PHYSICIANS FOLLOWING GUIDELINES? A REVIEW OF RADIATION ONCLOGY PRACTICE IN PATIENTS WITH UNCOMPPLICATED BONE METASTASES Vanessa Di Lalla1, Bernard Fortin2, Catherine Pembroke1, Carolyn Freeman1, Michael Yassa2, Tarek Hijal1; 1McGill University, Montreal, QC; 2Hôpital Maisonneuve Rosemont, Montreal, QC
<table>
<thead>
<tr>
<th></th>
<th>POSTER DISCUSSION SESSION 1</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>13</strong> OBJECTIVE EVALUATION OF A STRUCTURED DIDACTIC RADIATION ONCOLOGY CLERKSHIP CURRICULUM: A REPORT FROM THE RADIATION ONCOLOGY EDUCATION COLLABORATIVE STUDY GROUP</td>
<td><strong>18</strong> AUTOMATED CONTOURING OF THE PROXIMAL BRONCHIAL TREE USING OPEN SOURCE TOOLS FOR SBRT TREATMENT OF THE LUNG</td>
</tr>
<tr>
<td></td>
<td>Daniel Golden, Greg Kauffmann, Ryan McKillip, Alan Schwartz, Jeanne Farnan, Yoon Soo Park</td>
<td>Nirjan Venugopal, Vijayananda Kundapur, University of Saskatchewan, Saskatoon, SK</td>
</tr>
<tr>
<td></td>
<td>Radiation Oncology Education Collaborative Study Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td>¹University of Chicago, Chicago, IL; ²University of Illinois at Chicago, Chicago, IL; ³University of Illinois at Chicago, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>14</strong> A NEW FRONTIER: THE USE OF VIRTUAL SIMULATION FOR RADIATION THERAPY EDUCATION FOR BREAST CANCER PATIENTS</td>
<td><strong>19</strong> ONLINE ADVERTISING AND MARKETING CLAIMS BY PROVIDERS OF PROTON BEAM THERAPY: ARE THEY GUIDELINE BASED?</td>
</tr>
<tr>
<td></td>
<td>Jenny Soo, Christina Parsons, Christine Rodgerson, Jenny Seow, Paris-Ann Ingledew</td>
<td>Mark Corkum, Wei Liu, David Palma, Robert Dinniwell, Glenn Bauman, Andrew Warner, Mark Mishra, Alexander Louie</td>
</tr>
<tr>
<td></td>
<td>¹British Columbia Cancer Agency, Vancouver, BC; ²University of British Columbia, Surrey, BC</td>
<td>¹University of Western Ontario, London, ON; ²London Health Sciences Centre, London, ON; ³University of Maryland School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td></td>
<td><strong>15</strong> PROSPECTIVE LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND SYMPTOMS IN PATIENTS WITH OLIGOMETASTATIC CANCER TREATED WITH STEREOTACTIC BODY RADIATION THERAPY (SBRT): ANALYSIS OF A PHASE II TRIAL</td>
<td><strong>20</strong> ASSESSING HAZARD OF TOBACCO-RELATED CANCERS AMONG INDIVIDUALS WITH PSYCHIATRIC DISORDERS IN BRITISH COLUMBIA</td>
</tr>
<tr>
<td></td>
<td>Pablo Munoz-Schuffenegger, Tony Panzarella, Laura Dawson, Andrea Bezjak, Patricia Lindsay, Peter Chung, Andrew Hope, Meredith Giuliani, Anne Koch, Bernard Cummings, Zahra Kassam, Mojjan Taremni, Jolie Ringash, Rebecca Wong</td>
<td>Mary McClay, Robert Olson, Russ Callaghan</td>
</tr>
<tr>
<td></td>
<td>University of Toronto, Toronto, ON</td>
<td>¹University of British Columbia, Vancouver, BC; ²University of Northern British Columbia, Prince George, BC</td>
</tr>
<tr>
<td></td>
<td><strong>16</strong> PATIENT-REPORTED SEXUAL HEALTH AFTER DEFINITIVE CHEMORADIOThERAPY AND MR-GUIDED BRACHYTHERAPY FOR CERVIX CANCER</td>
<td><strong>21</strong> POPULATION-BASED STANDarIZED SYMPTOM SCREENING: CANCER CARE ONTARIO’S EXPANDED PROSTATE CANCER INDEX COMPOSITE FOR CLINICAL PRACTICE (EPIC-CP) PROVINCIAL IMPLEMENTATION APPROACH</td>
</tr>
<tr>
<td></td>
<td>Jennifer Croke, Rachel Gerber, Kathy Han, Jason Xie, Haiyan Jan, Akbar Beiki-Ardakani, Anthony Fyles, Michael Milosevic</td>
<td>Lisa Barbera, Farzana Haji, Michael Brundage, Colleen Bedford, Doris Howell, Brett Nicholls</td>
</tr>
<tr>
<td></td>
<td>Princess Margaret Cancer Centre, Toronto, ON</td>
<td>¹Ottawa Cancer Centre, Toronto, ON; ²Cancer Care Ontario, Toronto, ON; ³Cancer Centre of Southeastern Ontario, Kingston, ON; ⁴University Health Network, Toronto, ON</td>
</tr>
<tr>
<td></td>
<td><strong>17</strong> WITHDRAWN</td>
<td><strong>22</strong> RADIOTHERAPY FOR LUNG CANCER IN THE INTENSIVE CARE UNIT – A POPULATION BASED ANALYSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexander Louie, Lihua Li, Krista Bray Jenkyn, Britney Allen, Andrew Warner, George Rodrigues, David Palma, Salimah Shariff,</td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23</td>
<td>Patterns of Radiation Therapy Technology Use in the Treatment of Bone Metastases</td>
<td>Matthew Chan¹, Robert Olson², Shilo Lefresne², Michael McKenzie³</td>
</tr>
<tr>
<td>24</td>
<td>Multicenter Evaluation of the Tolerability of Combined Treatment with PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiotherapy</td>
<td>Andrew Bang¹, Tyler Wilhite², Luke Pike², Daniel Cagney³, Ayal Aizer³, Alexander Spektor³, Monica Krishnan³, Patrick Ott³, Tracy Balboni³, Stephen Hodi³, Jonathan Schoenfeld³</td>
</tr>
<tr>
<td>27</td>
<td>Myxofibrosarcoma Characteristics and Clinical Outcomes at a Large Canadian Tertiary Cancer Referral Centre</td>
<td>Gaurav Bhattacharya, Matthew Tsang, Horia Marginean, Samy El Sayed</td>
</tr>
<tr>
<td>28</td>
<td>A Systematic Review of Clinical Outcomes Following Chemoradiotherapy for Anal Cancer in HIV-Positive Patients on Highly-Active Anti-Retroviral Therapy (HAART)</td>
<td>Rohann Correa¹, Robert Dinniwell², Boris Virine³, Adeel Kaiser⁴, Mark Mishra⁴, Alexander Louie⁴</td>
</tr>
<tr>
<td>29</td>
<td>Neoadjuvant SBRT for Pancreatic Ductal Adenocarcinoma: A Systematic Review</td>
<td>Rahul Arora¹, Jan Grendar², Petra Grendarova³, Zeljka Jutric³, Richie Sinha³</td>
</tr>
<tr>
<td>30</td>
<td>Factors Affecting Post-Operative Cavity Volume and Surface Area Dynamics Specific to Brain Metastases</td>
<td>Yaser Hasan¹, Luluel Khan¹, Todd Mainprize¹, Sunit Das¹, Mark Ruschin¹, Fiona Lochray², Young Lee², May Tso³, Arjun Sahgal³, Hany Soliman³</td>
</tr>
<tr>
<td>31</td>
<td>Outcomes of Hypofractionated Stereotactic Radiotherapy for Intracranial Meningioma: A Systematic Review of the Literature</td>
<td>Timothy Nguyen¹, Eric Nguyen¹, Hanbo Chen¹, R Gabe Boldit¹, Alexander Louie¹, Glenn Bauman¹, London Health Sciences Centre, London, ON; ²Juravinski Cancer Centre, Hamilton, ON</td>
</tr>
<tr>
<td>32</td>
<td>Checkpoint Slippage After DNA Double Strand Breaks Underlies Activation of IR-Induced Inflammatory Signaling</td>
<td>Shane Harding, Joseph Benci, Jerome Irianto, Dennis Discher, Andy Minn, Greenberg Roger</td>
</tr>
</tbody>
</table>
4:00-5:00  FELLOW COMPETITION  Toronto I/II

Moderators: Michael Brundage, Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to review Canadian Radiation Oncology Fellow Research Projects.

33  ELEKTA FELLOWSHIP  DOSSIMETRIC IMPACT OF RE-PLANNING DURING A COURSE OF CURATIVE INTENT HEAD AND NECK RADIATION TREATMENT  Theodora A Koulis¹, Quinn Matthews¹, Nick Chng¹, Bronwen Engel¹, Boris Valev¹, Robert Olson²; ¹British Columbia Cancer Agency, Prince George, BC; ²University of British Columbia, Vancouver, BC

34  PLERIXAFOR IMPROVES PRIMARY TUMOUR RESPONSE AND REDUCES NODAL METASTASIS IN CERVICAL CANCER TREATED WITH RADIOCHEMOTHERAPY  Magali Lecavalier-Barsoum¹, Naz Chaudary², Pratibha Tapa³, Meegan Larsen⁴, Melania Pintilie⁵, Ri Wang⁶, Kathy Han⁷, Laura Caporiccio⁸, Richard Hill⁹, Michael Milosevic¹; ¹Princess Margaret Cancer Centre, Toronto, ON; ²University of Western Ontario, London, ON; ³Credit Valley Hospital, Mississauga, ON

35  PATTERNS OF IPSILATERAL REGIONAL NODAL RELAPSE IN BREAST CANCER: A REVIEW OF THE RTOG BREAST CANCER ATLAS  Laura Beaton¹, Luminita Nica², Gareth Ayre², Kenny Sek², Maria Aparicio², Lovedeep Gondara², Caroline Speers², Scott Tyldesley², Alan Nichol³; ¹British Columbia Cancer Agency, Vancouver, BC; ²University of British Columbia, Vancouver, BC

5:15-6:15  ANNUAL GENERAL MEETING  (for members)  Toronto I

6:15-8:15  POSTER VIEWING AND WELCOME RECEPTION  Convention Level Foyer
FRIDAY SEPTEMBER 15, 2017

7:30-8:30  REGISTRATION AND BREAKFAST  Convention Level

8:30-8:45  WELCOME AND INTRODUCTIONS  Fabio Cury  Toronto VII

8:45-9:45  GORDON RICHARDS LECTURE

Moderator: Padraig Warde

Advocating for Quality…  Michael Brundage

OBJECTIVES: At the end of this session, the participants will be able to:

| Reflect on advocacy for quality in a number of dimensions, both past and present. |
| Discuss links between the CanMEDS educational roles framework and advocacy for quality of care in radiation oncology. |

9:45-10:45  RESIDENT COMPETITION

Moderator: Claire Snyder

OBJECTIVES: At the end of this session, the participants will be able to review Canadian Radiation Oncology Resident Research Projects.

39  PREDICTING THE FAILURE OF RANDOMIZED CONTROLLED TRIALS IN RADIATION ONCOLOGY: WHAT CAN WE LEARN?  Timothy Nguyen1, Eric Nguyen2, Andrew Warner1, Alexander Louie1, David Palma1; 1London Health Sciences Centre, London, ON; 2Juravinski Cancer Centre, Hamilton, ON

40  STEREOTACTIC ABLATIVE RADIOTHERAPY VERSUS SURGERY IN EARLY LUNG CANCER: A META-ANALYSIS OF PROPENSITY SCORE-ADJUSTED COMPARATIVE EFFECTIVENESS STUDIES  Hanbo Chen1, Joanna Laba2, Rachel Gabriel Boldt1, Christopher Goodman1, David Palma3, Suresh Senan1, Alexander Louie1; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON; 3VVU University Medical Center, Amsterdam, North Holland, Netherlands

41  IMPROVED DISEASE CONTROL WITH ADJUVANT THERAPY FOR STAGE IA SEROUS AND CLEAR CELL UTERINE CANCER: A POOLED MULTI-INSTITUTIONAL ANALYSIS  Xuanlu Qu1, Vikram Velker2, Eric Leung3, Janice Kwon3, Mohamed Elshaikh4, Iwa Kong5, Natalie Logie6, Lucas Castro Mendez6, Louis van der Putten6, Elysia Donovan6, Adnan Munkarah6, Ericka Wiebe7, Alexander Louie8, David D’Souza8; 1Queen’s University, Kingston, ON; 2University of Western Ontario, London, ON; 3University of Toronto, Toronto, ON; 4University of British Columbia, Vancouver, BC; 5Henry Ford Hospital, Detroit, MI; 6McMaster University, Hamilton, ON; 7University of Alberta, Edmonton, AB; 8Gynecology/Oncology, Detroit, MI; 9London Health Sciences Centre, London, ON

42  CBCT-derived radiotherapy marker associated with radiation pneumonitis  Pencilla Lang1, Douglas Moseley2, Uffe Bernchou3, Carsten Brink4, Andrew Hope1; 1University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON; 3Odense University Hospital, Odense, Denmark

43  STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC AND OLIGOPROGRESSIVE DISEASE  Catherine Pembroke, Neil Kopek; McGill University, Montreal, QC

44  VALIDATION OF THE TEACHH SCORE FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTASIS TO THE SPINE  Maryam Dosani1, Sarah Hamilton1, Tim Kong2, Sarah Lucas1, Jordan Wong1, Mitchell Liu1, Scott Tyldesley1; 1British Columbia Cancer Agency, Vancouver, BC; 2University of British Columbia, Vancouver, BC

10:45-11:30  Break/Exhibitor Showcase
At the end of this session, the participants will be able to:
1. Understand modern approaches in the treatment of lung cancer using SBRT.

**OBJECTIVES:**

**Moderators:** Juanita Crook, Guila Delouya

**ORAL SESSION 3 – LUNG CANCER**

**Toronto I**

11:30-12:30

**METABOLIC TUMOUR VOLUME IS PROGNOSTIC OF OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH STEREOTACTIC ABLATIVE RADIOTHERAPY**

Maryam Dosani1, Rob Olson1, Ruobing Yang1, Don Wilson1, Mitchell Liu1, Charlotte J Yong-Hing1, Jeremy Hammi1, Chad R Lund1, Devin Schellenberg2; 1British Columbia Cancer Agency, Vancouver, BC; 2British Columbia Cancer Agency, Surrey, BC

**CENTRAL 3D: A CLINICIAN TOOL FOR ROBUST CHARACTERIZATION OF CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER**

Dominique Mathieu, Vincent Cousineau Daoust, Laurent Bilodeau, Stéphane Bedwani, Édith Filion, Alexis Lenglet, Houda Bahig, David Roberge, Marie-Pierre Campeau; Université de Montréal, Montréal, QC; Centre hospitalier de l’Université de Montréal, Montréal, QC

**FUNCTIONAL LUNG AVOIDANCE FOR INDIVIDUALIZED RADIOTHERAPY (FLAIR): RESULTS OF A RANDOMIZED, DOUBLE-BLIND CLINICAL TRAIL**

Brian Yaremko1, Dante Capaldi1, Khadija Sheikh1, A Rashid Dari1, Edward Yu1, Alexander Louie2, George Rodrigues1, Stewart Gaede1, Jeff Chen1, Abigail Erickson2, Andrew Warner2, Brian Dingle1, Mark Landis1, Mark Vincent1, Michael Sanatani1, Jawaid Younus1, M Sara Kuruvi1, David Palma1, Grace Parraga1; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON

**IS STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) SAFE FOR THE TREATMENT OF ULTRA-CENTRAL LUNG TUMOURS? A SYSTEMATIC REVIEW**

Joanna Laba1, Hanbo Chen1, Gabriel Boldt2, David Palma1, Alexander Louie2; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON

**CARO ELEKTA CONDITIONAL SURVIVAL PROBABILITIES FOLLOWING SABR IN EARLY-STAGE NON-SMALL CELL LUNG CANCER**

Alexander Louie1, Mark Mishra2, Frank Lagerwaard3, Cornelis Haasbeek1, Ben Slotman2, Suresh Senan3; 1London Regional Cancer Program, London, ON; 2University of Maryland School of Medicine, Baltimore, MD; 3VU University Medical Center, Amsterdam, Netherlands

**DEFINING THE NEED FOR PALLIATIVE LUNG CANCER RADIOTHERAPY IN THE GENERAL POPULATION: A CRITERION-BASED BENCHMARKING APPROACH**

Chunzi Jenny Jin, Weidong Kong, William Mackillop; Queen’s University, Kingston, ON

**FUNCTIONAL LUNG AVOIDANCE FOR INDIVIDUALIZED RADIOTHERAPY (FLAIR): RESULTS OF A RANDOMIZED, DOUBLE-BLIND CLINICAL TRAIL**

Brian Yaremko1, Dante Capaldi1, Khadija Sheikh1, A Rashid Dari1, Edward Yu1, Alexander Louie2, George Rodrigues1, Stewart Gaede1, Jeff Chen1, Abigail Erickson2, Andrew Warner2, Brian Dingle1, Mark Landis1, Mark Vincent1, Michael Sanatani1, Jawaid Younus1, M Sara Kuruvi1, David Palma1, Grace Parraga1; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON

**IS STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) SAFE FOR THE TREATMENT OF ULTRA-CENTRAL LUNG TUMOURS? A SYSTEMATIC REVIEW**

Joanna Laba1, Hanbo Chen1, Gabriel Boldt2, David Palma1, Alexander Louie2; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON

**CARO ELEKTA CONDITIONAL SURVIVAL PROBABILITIES FOLLOWING SABR IN EARLY-STAGE NON-SMALL CELL LUNG CANCER**

Alexander Louie1, Mark Mishra2, Frank Lagerwaard3, Cornelis Haasbeek1, Ben Slotman2, Suresh Senan3; 1London Regional Cancer Program, London, ON; 2University of Maryland School of Medicine, Baltimore, MD; 3VU University Medical Center, Amsterdam, Netherlands

**DEFINING THE NEED FOR PALLIATIVE LUNG CANCER RADIOTHERAPY IN THE GENERAL POPULATION: A CRITERION-BASED BENCHMARKING APPROACH**

Chunzi Jenny Jin, Weidong Kong, William Mackillop; Queen’s University, Kingston, ON
55 FACTORS ASSOCIATED WITH IN-FIELD RECURRENT IN PATIENTS TREATED WITH LIVER SBRT Emily Hubley1, Sarah Quirk1, Richie Sinha1, Shaun Loewen1, Petra Grendarova2;
1University of Calgary, Calgary, AB; 2Tom Baker Cancer Centre, University of Calgary, Calgary, AB

56 PROGRESSIVE HYPO FRACTIONATED IGRT REGIMENS: TOXICITY, ACCEPTABILITY AND EFFICIENCY OF DELIVERY COMPARED TO A STANDARD FRACTIONATION REGIMEN, BOTH WITH HDR BRACHYTHERAPY BOOST André-Guy Martin1, Khaly Mbojdj2, William Foster1, Éric Vigneault1, Philippe Després2, Marie-Claude Lavallée1, Frédéric Lacroix1, Nadia Octave1;
1Centre Hospitalier Universitaire de Québec – L’Hôtel-Dieu de Québec, Québec, QC; 2Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec QC

OBJECTIVES:
12:30-2:30-3:30

1 2 3 4 5 6

2:30-3:30

Lunch Break

COMMITEE MEETINGS Please refer to the Committee Meetings Schedule for exact times

2:30-3:30

CANADIAN BRACHYTHERAPY GROUP ORAL SESSION Toronto I

Moderator: Marc Gaudet, Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to:

I Recognize the most recent advances on brachytherapy research for prostate and cervical cancer.
I Discuss the results of a Phase III trial on brachytherapy for lung cancer.

57 TOXICITY AND HEALTH-RELATED QUALITY OF LIFE RESULTS OF 2-FRACTION HDR BRACHYTHERAPY AS MONOTHERAPY FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER Marc Gaudet1, Mathieu Pharand-Charbonneau2, Debbie Wright2, Marie-Pierre Desrosiers2, Alain Haddad2; 1The Ottawa Hospital, Ottawa, ON; 2CISSS de l’Outaouais, Gatineau, QC; 3University of Ottawa, Ottawa, ON

58 US-PLANNED HDR PROSTATE BRACHYTHERAPY BOOST: ACUTE AND LATE TOXICITY Laurie Pilote1, Juanita Crook1, Miren Gaztañaga2, Ana Ots1, Jasbir Jaswal1, Jim Rose1, Audrey Tetreault Lafliamme2, Cynthia Araujo1, Batchelor Deidre1, Marie-Pierre Millette1, Schmid Matthew1, Martin Korzeniowski1, Francois Bachand1;
1British Columbia Cancer Agency, Kelowna, BC; 2Departamento Oncología Radioterapia, Madrid, Spain; 3United Lincolnshire Hospitals, Lincoln, United Kingdom; 4British Columbia Cancer Agency, Fraser Valley, BC; 5British Columbia Cancer Agency, Abbotsford, BC; 6Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC

59 ELECTROMAGNETIC RECONSTRUCTION OF CATHERER PATHS IN MULTI-CATHETER INTERSTITIAL BRACHYTHERAPY: A PHANTOM MODEL Harry C Brasilanos1, Thomas Vaughan1, Andras Lasso1, Tamas Ungi1, Mary Westerlund1, James Gooding2, Gabor Fichtinger1, Conrad Falkson1; 1Queen’s University, Kingston, ON; 2Kingston General Hospital, Kingston, ON

60 A PHASE III, MULTI-CENTRE, RANDOMIZED TRIAL TO EVALUATE THE SYMPTOMATIC AND QUALITY OF LIFE IMPROVEMENTS IN LUNG CANCER PATIENTS RECEIVING EXTERNAL BEAM RADIATION WITH OR WITHOUT HIGH DOSE RATE INTRALUMINAL BRACHYTHERAPY Ranjan Sur1, Conrad Falkson2, Ming Pan3, Greg Pond1, Jim Wright4, Andrea Bezjak4, Anne Dagnault5, Robert Hunter1, Edward Yu6, Maha Almahmudi4, Sundeep Shahi1, Serhij Puksa1, Daren Gopaul7, Theodorus Tsakridis1, Anand Swaminath1, Peter Ellis1, Kathryn Kline1, Catherine Bucci1, Sheikh Nisar Ahmed6, Timothy Whelan1; 1McMaster University, Hamilton, ON; 2Queen’s University, Kingston, ON; 3Windsor Regional Cancer Centre, Windsor, ON; 4Juvavinski Cancer Centre, Hamilton, ON; 5Princess Margaret Cancer Centre, Toronto, ON; 6Hotel-Dieu de Québec, CHUQ, Quebec City, QC; 7University of Western Ontario, London Regional Cancer Centre, London, ON; 8British Columbia Cancer Agency, Abbotsford, BC; 9Grand River Regional Cancer Centre, Kitchener, ON

61 THE CURRENT LANDSCAPE OF QUALITY ASSURANCE PRACTICES FOR CERVIX BRACHYTHERAPY IN CANADA Jocelyn Moore1, Peter Lim1, Jennifer Croke2, Corinne Doll3, Fleur Huang2, Teri Stickless3, Maroie Barkati4, Christina Parsons4; 1British Columbia Cancer Agency, Vancouver, BC; 2Princess Margaret Cancer Centre, Toronto, ON; 3Tom Baker Cancer Centre, Calgary, AB; 4Cross Cancer Institute, Edmonton, AB; 5Dr H Bliss Murphy Cancer Centre, St John’s, NL; 6Centre hospitalier de l’Université de Montréal, Montreal, QC

62 A COST-UTILITY ANALYSIS COMPARING MR-GUIDED BRACHYTHERAPY TO 2D BRACHYTHERAPY FOR MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER IN ONTARIO, CANADA Julia Skliarenko1, Johanna Perdrizet1, Michelle Ang2, Lisa Barbera3, Eric Gutierrez3, Ananth Ravi4, Kari Tanderup4, Padraig Warde4, David D’Souza5, Kelvin Chan5, Wanrudee Isaranuwatchai2, Michael Milosevic5; 1Simcoe Muskoka Regional Cancer Program, Barrie, ON; 2St Michael’s Hospital, Toronto, ON; 3CancerCare Ontario, Toronto, ON; 4University of Toronto, Toronto, ON; 5Aarhus University Hospital, Aarhus, Denmark; 6London Health Sciences Centre, London, ON; 7Odette Cancer Centre, Toronto, ON
3:30-4:30 ORAL SESSION 5 – RADIATION TREATMENT, RADIOSURGERY Toronto I
Moderator: Francois Bachand, David Palma

OBJECTIVES: At the end of this session, the participants will be able to:
I Discuss important factors related to quality of treatment planning and delivery.
I Understand the most recent advances in radiosurgery and its impact on treatment outcomes.

63 SURVIVAL IMPACT OF CARDIAC DOSE IN LUNG STEREOTACTIC BODY RADIOThERAPY Olive Wong1, Vivian Yau1, Julie Kang1, Daniel Glick2, Patricia Lindsay3, Lisa Le3, Alexander Sun3, Andrea Bezik3, John Cho3, Andrew Hope3, Meredith Giulian3; 1Princess Margaret Cancer Centre, Toronto, ON; 2British Columbia Cancer Agency, Vancouver, BC; 3University of Toronto, Toronto, ON

64 ASSESSMENT OF DOSIMETRIC PREDICTORS AND IMPACT OF WHOLE-BRAIN RADIOTHERAPY ON THE INCIDENCE OF RADIONECROSIS AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASIS Hamid Razaee1, Fabio Y Moran2, Young-Bin Cho2, Manjula Magnati1, David Shultz2, Barbara-Ann Millar1, Normand Laperriere1, Caroline Chung3, Alejandro Berlin2; 1University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON; 3MD Anderson Cancer Center, University of Texas, Houston, TX

65 EXTREME HYPOFRACTIONATION FOR HIGH RISK PROSTATE CANCER: DOSIMETRIC CORRELATIONS WITH RECTAL BLEEDING Glenn Bauman1, Jeff Chen2, George Rodrigues1, Kristina Commissio3, Alexandre Mamedov4, Hima Musunuru4, Melanie Davidson5, Tristan Mills1, Andrew Warner1, Andrew Loblaw4; 1London Regional Cancer Program, London, ON; 2University of Western Ontario, London, ON; 3Sunnybrook Odette Cancer Centre, Toronto, ON; 4University of Toronto, Toronto, ON; 5University of Wisconsin School of Medicine and Public Health, Madison, WI

3:30-4:30 ORAL SESSION 6 – GYNECOLOGIC CANCER Toronto II
Moderators: Joanne Alfieri, Jennifer Croke

OBJECTIVES: At the end of this session, the participants will be able to:
I Discuss treatment planning, quality of life, and outcomes of radiotherapy for gynecological tumours.
I Review possible factors that can be associated with treatment outcomes in the management of gynecologic malignancies.

66 OUTCOMES FOR IMAGE-GUIDED FRAMELESS LINEAR ACCELERATOR-BASED HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY IN FIVE DAILY FRACTIONS TO THE SURGICAL CAVITY AFTER RESECTION OF BRAIN METASTASES Hany Soliman1, Sten Myrehaug2, May Tsao1, Chia-Lin Tseng1, Ahmed Hashmi1, Mark Ruschin1, Young Lee1, Arjun Sahgali; 1Odette Cancer Centre, University of Toronto, Toronto, ON; 2Clatterbridge Cancer Centre, Merseyside, UK

67 POST-SURGICAL CLIPS AS FIDUCIALS FOR TREATMENT OF STEREOTACTIC BODY RADIOTHERAPY OF THE LIVER Muhammad Faisal Jamaluddin, Kurian Joseph, Diane Severin, Joel St Aubin, Adele Duimmering, Shannah Murland, Zsolt Gabos, Keith Tankel; University of Alberta, Edmonton, AB

68 ESOPHAGEAL TOXICITY IN THORACIC STEREOTACTIC RADIOTHERAPY Vivian Yau1, Patricia Lindsay3, Andrew Hope1, Lisa Le1, Daniel Glick2, Anthea Lui2, John Cho2, Andrea Bezik3, Alex Sun3, Meredith Giulian3; 1Princess Margaret Cancer Centre, Toronto, ON; 2British Columbia Cancer Agency, Victoria, BC

69 PRECLINICAL ASSESSMENT OF ACUTE AND LATE GASTROINTESTINAL TOXICITY WITH THE ADDITION OF PLERIXAFOR TO RADIO – CHEMOTHERAPY FOR CERVICAL CANCER Naz Chaudary1, Magali Lecavalier-Barsoumi1, Pratibha Thapa1, Meegan Larsen2, Melanie Pintilie1, Kathy Han1, Richard Hill1, Michael Milosevic1; 1Princess Margaret Cancer Centre, Toronto, ON; 2Mt. Sinai Pathology, Toronto, ON

70 VALIDATION OF PATIENT REPORTED OUTCOME MEASURES IN PATIENTS RECEIVING HIGH DOSE PELVIC RADIATION THERAPY FOR GYNECOLOGIC MALIGNANCIES Matthew Chan1, Vincent Lapointe1, Robert Olson2, Caroline Holloway4, Francois Bachand4, Peter Lim1, Christina Parsons1; 1British Columbia Cancer Agency, Vancouver, BC; 2University of British Columbia, Vancouver, BC; 3British Columbia Cancer Agency, Vancouver Island, BC; 4British Columbia Cancer Agency, Kelowna, BC

71 ADJUVANT CHEMO-RADIATION FOR CLEAR CELL CARCINOMA OF THE OVARY: A POPULATION BASED STUDY OF PELVIC VERSUS WHOLE ABDOMINAL RADIATION THERAPY Soumyajit Roy1, Anna Tinker2, Paul Hoskins2, Francois Bachand3, Caroline Holloway4, Christina Parsons1, Peter Lim2, Gaurav Bah1; 1British Columbia Cancer Agency, Abbotsford, BC; 2British Columbia Cancer Agency, Vancouver, BC; 3British Columbia Cancer Agency, Kelowna, BC; 4British Columbia Cancer Agency, Vancouver Island, BC
CONTOURING AND TARGET VARIABILITY IN VAGINAL TUMOURS TREATED WITH MR-BASED INTERSTITIAL BRACHYTHERAPY: A MULTI-CENTRE CANADIAN CONTOURING STUDY

Eric Leung1, David D’Souza2, Joanne Alfieri3, Robyn Banerjee4, Francois Bachand5, Lisa Barbera6, Maroie Barkati7, Toni Barnes3, David Bowes3, Israel Forkin7, William Foster9, Kathy Han19, Fleur Huang11, Nikhiles Patil11, Vikram Velker3, Eric Vigneault9, Ericka Wiebe11, Matt Wronski6, Ananth Ravi11; 1University of Toronto, Toronto, ON; 2London Health Sciences Centre, London, ON; 3McGill University Health Centre, Montreal, QC; 4Tom Baker Cancer Centre, Calgary, AB; 5British Columbia Cancer Agency, Kelowna, BC; 6Sunnybrook Health Sciences Centre, Toronto, ON; 7CHUM – Hôpital Notre-Dame, Montreal, QC; 8Nova Scotia Cancer Centre, Halifax, NS; 9Centre Hospitalier Universitaire de Quebec, Quebec, QC; 10Princess Margaret Cancer Centre, Toronto, ON; 11Cross Cancer Institute, Edmonton, AB

PIK3CA MUTATIONAL STATUS AND POST CHEMORADIOThERAPY 18F-FDG-PET IMAGING RESPONSE IN PATIENTS WITH CERVICAL CANCER

Kevin Martell, John McIntyre, Elizabeth Kornaga, Angela Chan, Tien Phan, Martin Koebel, Prafull Ghatage, Susan Lees-Miller, Corinne Doll; University of Calgary, Calgary, AB

3D IMAGE GUIDED INTERSTITIAL BRACHYTHERAPY FOR PRIMARY VAGINAL CANCER

Chris Goodman1, Vikram Velker2, Eric Leung3, Alexander V Louie4, George Hajdok1, Nikhiles Patil3, Ericka Wiebe4, David D’Souza1; 1University of Western Ontario, London, ON; 2University of Toronto, Toronto, ON; 3Dalhousie University, Halifax, NS; 4University of Alberta, Edmonton, AB

WORKSHOPS

QUALITY ASSURANCE IN PALLIATIVE RADIATION THERAPY AND SYMPTOM CONTROL

Kristopher Dennis

OBJECTIVES: At the end of this workshop, the participants will be able to:

- Appreciate the need for, and the complexity of providing quality assurance for non-stereotactic palliative radiation therapy and symptom control.
- Understand the current state of peer review practices in Canada for non-sterotactic palliative radiation therapy.
- Be aware of best practice resources for non-stereotactic palliative radiation therapy and symptom control.
- Be aware of potential future metrics for measuring quality within this environment.

WHY WOULDN’T YA? A WIN/WIN STRATEGY USING ADVANCED PRACTICE RADIATION THERAPISTS

Nicole Harnett, Robert Dinniwell, Padraig Warde, Grace Lee

OBJECTIVES: At the end of this workshop, the participants will be able to:

- Describe what an Advanced Practice Radiation Therapist (CSRT) is and provide examples of the work that CSRTs are currently doing in Ontario.
- Discuss the pressures currently facing the radiation medicine domain and how CSRTs could play a role in alleviating these pressures.
- Identify opportunities to permanently integrate CSRTs into the radiation medicine team.

PAN-CANADIAN PRO COLLECTION: WORKING TOGETHER TO ADVANCE PATIENT CARE

Robert Olson, Lisa Barbera, Amanda Caisse, Michael Milosevic, Erika Brown

OBJECTIVES: At the end of this workshop, the participants will be able to:

- Learn about what patient reported outcomes are and how they can help improve clinical care, symptom control and patient outcomes.
- Learn about the British Columbia Cancer Agency’s Prospective Outcomes and Support Initiative (POSI) and Cancer Care Ontario’s Patient Reported Outcome Program.
- Discuss how standardizing PRO collection models in specific disease sites can advance quality of care in patient populations across the country and how the Canadian Partnership for Quality Radiotherapy is helping facilitate and drive pan – Canadian alignment.
- Learn ways to increase the utility of PRO within practice.
SATURDAY SEPTEMBER 16, 2017

7:15-8:15  DR PAMELA CATTON MEMORIAL FUN RUN/WALK
Meet at the University Avenue Lobby Door at 7:00am.

8:30-9:30  COMMITTEE MEETINGS  Please refer to the Committee Meetings Schedule for exact times
8:30-9:30  REGISTRATION AND BREAKFAST

9:30-10:30  Jean Roy Lecture  Toronto I
Moderator: Eric Vigneault
Brachytherapy Education in an Era of High Technology
Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to:
| Identify limitations of current training in brachytherapy. |
| Describe how Royal College Area of Focused Competency (AFC) Diploma programs might address these needs. |

10:30-11:30  ORAL SESSION 7 – HEAD AND NECK CANCER  Toronto I
Moderators: Anand Karvat, David Petrik

OBJECTIVES: At the end of this session, the participants will be able to:
| Describe important factors associated with the improvement of treatment outcomes for patients with head and neck malignancies. |
| Review possible methods to decrease toxicity during radiation therapy for head and neck cancers. |

75  STEREOTACTIC BODY RADIOTHERAPY (SBRT) PROVIDES AN EXCELLENT LOCAL CONTROL WITH ACCEPTABLE TOXICITIES IN MEDICALLY UNFIT HEAD AND NECK CANCER PATIENTS
Hossam Al-Assaf, Ian Poon, Justin Lee, Irene Karam, Kevin Higgins, Danny Enepekides; University of Toronto, Toronto, ON

76  EARLY (90-DAY) MORTALITY AFTER RADICAL RADIOTHERAPY FOR HEAD & NECK SQUAMOUS CELL CARCINOMA: A POPULATION-BASED ANALYSIS
Sarah Hamilton1, Eric Tran1, Eric Berthelet1, Jonn Wu2, Robert Olson3; 1British Columbia Cancer Agency, Vancouver, BC; 2University of British Columbia, Vancouver, BC

77  DISTANT METASTASES RISK-GROUP DEFINITION OF ORAL SQUAMOUS CELL CARCINOMA PATIENTS TREATED WITH POSTOPERATIVE INTENSITY MODULATED RADIOTHERAPY
Ali Hosni, Kevin Chiu, Shao Hui Huang, Wei Xu, Jie Su, Li Tong, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, John Kim, Jolie Ringash, John Waldron, John de Almeida, Douglas Chepeha, David Goldstein, Brian O’Sullivan, Andrew Hope; Princess Margaret Cancer Centre, Toronto, ON

78  A RADIOMIC PROGNOSTIC INDEX REFINES RISK MODELS FOR DISTANT METASTASIS IN HPV-RELATED OROPHARYNGEAL CANCER
Jennifer Kwan1, Jie Su1, Shao Hui Huang2, Wei Xu2, Kenneth Yip2, Meredith Giuliani2, Andrew Bayley2, John Kim1, Andrew Hope2, Jolie Ringash1, John Cho1, Andrea McNiven2, Aaron Hansen1, David Goldstein1, Hugo Aerts4, John Waldron1, Benjamin Haebe-Kains2, Brian O’Sullivan1, Scott Bratman1, Fei-Fei Liu2; 1University of Toronto, Toronto, ON; 2University Health Network, Toronto, ON; 3University of British Columbia, Vancouver, BC; 4Princess Margaret Cancer Centre, Toronto, ON

79  EVALUATION OF DIFFERENCES BETWEEN ESTIMATED DELIVERED DOSE AND PLANNED DOSE IN NASOPHARYNX PATIENTS USING DEFORMABLE IMAGE REGISTRATION AND DOSE ACCUMULATION
Olive Wong1, Andrea McNiven2, Blu Chan3, Joanne Moseley1, Jenny Lee1, Lisa Le1, Cijian Ren1, John Waldron1, Jean-Pierre Bissonnette2, Meredith Giuliani2, Beibei Zhang3; 1Princess Margaret Cancer Centre, Toronto, ON; 2University of Toronto, Toronto, ON; 3University Health Network, Toronto, ON

80  TREATMENT OUTCOMES IN OROPHARYNX CANCER PATIENTS WHO RECEIVED LESS THAN THE PLANNED CURATIVE RADIOTHERAPY DOSE
Fatimah Alfaraj1, Shao Hui Huang1, Brian O'Sullivan1, Jie Su1, Andrew Bayley1, Scott Bratman1, John Cho1, Meredith Giuliani1, John Kim1, Jolie Ringash1, John Waldron1, Aaron Hansen1, Ana Spreafico1, John de Almeida1, Bayardo Perez-Ordonez2, Ilan Weinreb2, Li Tong2, Wei Xu2, Andrew Hope3; 1University of Toronto, Toronto, ON; 2University Health Network, Toronto, ON; 3University of British Columbia, Vancouver, BC; 4Princess Margaret Cancer Centre, Toronto, ON
10:30-11:30  **ORAL SESSION 8 – CNS, EXPERIMENTAL THERAPEUTICS Toronto II**

**Moderators:** Valerie Panet-Raymond, Irene Karam

**OBJECTIVES:** At the end of this session, the participants will be able to:

1. Review important aspects associated with treatment delivery and outcomes of patients undergoing treatment for CNS tumours.
2. Describe relevant biomarkers for effectiveness and toxicity of cancer therapy.

---

**81 CLINICAL OUTCOMES OF 24 GY IN 2 DAILY FRACTIONS FOR PATIENTS WITH DE NOVO SPINAL METASTASES TREATED WITH SPINE STEREOTACTIC BODY RADIOThERAPY (SBRT)**

Chia-Lin Tseng, Mikki Campbell, Hany Soliman, Sten Myrehaug, Mark Ruschin, Young Lee, Eshetu Atenafu, Arjun Sahgal; University of Toronto, Toronto, ON

**82 PROGNOSTIC FACTORS IN ATYPICAL MENINGIOMA**

Luis Souhami, Shakir Shakir, Kevin Petrecca, Jose Joao Mansure, George Shenouda, Valerie Panet-Raymond, Bassam Abdulkarim, Marie Christine Guiot; McGill University Health Centre, Montréal, QC

**83 CANADIAN PATTERNS OF PRACTICE FOR INTRACRANIAL GERM CELL TUMOURS IN ADOLESCENTS AND YOUNG ADULTS**

Andrea Lo1, Normand Lapeniere1, David Hodgson1, Eric Bouffet1, James Nicholson1, Michael McKenzie1, Juliette Hukin1, Karen Goddard1; 1University of Toronto, Toronto, ON; 2University of British Columbia, Vancouver, BC

---

**11:30-12:15  Lunch**

12:15-1:45  **WORKSHOPS**

**WORKSHOP 4 Governor General**

**CHEST TUMOURS: CHALLENGES IN PRACTICE**

Patricia Tai, Conrad Falkson, Arjun Sahgal, Meredith Giuliani

**OBJECTIVES:** At the end of this workshop, the participants will be able to:

1. Be competent on the application of various radiation treatment techniques, with respect to target volume definition and doses for different tumors in the chest, including mesothelioma and thymoma.
2. Be familiar with re-irradiation treatment planning, and tolerance doses.

**WORKSHOP 5 Toronto III**

**STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR SPINAL METASTASES**

Majed Alghamdi, Arjun Sahgal, Young Lee, Laura Masucci

**OBJECTIVES:** At the end of this workshop, the participants will be able to:

1. Understand the indications, outcomes and toxicities of Spine SBRT.
2. Know the surgical innovations in combination with SBRT.
3. Describe target volumes, prescription dose and constraints for OARs.
4. Evaluate SBRT plan.
5. Know the QA process for spine SBRT.
6. Understand SC24- Canadian Randomized Trial (20Gy /5 vs SBRT 24 Gy/2).
WORKSHOP 6  Tom Thomson

BUILDING A COMMUNITY OF PRACTICE THROUGH CARO TO PROMOTE QUALITY RADIOTHERAPY
Amanda Caissie, Michael Brundage, Brian Liszewski, Christina Parsons, Gunita Mitera

OBJECTIVES: At the end of this workshop, the participants will be able to:

I Understand what quality and best practice means for radiotherapy (RT).
I Discuss examples of key quality improvement initiatives currently underway across Canadian RT centres and promoted through national organizations/initiatives such as the Canadian Partnership for Quality Radiotherapy (CPQR) or National Peer Review Study.
I Identify to the CARO Quality and Standards Committee for rationale for its creations.
I Discuss how both academic and community Canadian RT centres could benefit from the committee as a community of practice (COP) driving RT QI initiatives.

1:45-2:45  REVIEWERS’ CHOICE  Toronto I

Moderators: Andrea Bezjak, Marc Gaudet

OBJECTIVES: At the end of this session, the participants will be able to:

I Understand a variety of interesting and select topics of radiation therapy innovations, quality of care, and quality of life measurements and how these
I Impact our cancer population.

87  INDIVIDUAL PATIENT DATA META-ANALYSIS OF KIDNEY SBRT: A REPORT FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM FOR KIDNEY (IROCK) Alexander Louie1, Alexander Muacevic2, Michael Staehler2, Andrew Warner3, Senthilkumar Gandhinasan4, Lee Ponsky5, Rodney Ellis5, Irving Kaplan6, Anand Mahadevan6, William Chu6, Hiroshi Onishi8, Simon Lo9, Bin Teh10, Anand Swaminath11, Rohann Correa12, Shankar Siva12; 1London Regional Cancer Program, London, ON; 2University of Munich, Munich, Germany; 3London Health Sciences Centre, London, ON; 4University of Melbourne, Melbourne, Australia; 5Case Western Reserve University, Cleveland, OH; 6Harvard University, Boston, MA; 7University of Toronto, Toronto, ON; 8University of Yamanashi, Yamanashi, Japan; 9University of Washington, Seattle, WA; 10Weil Cornell Medical College, Houston, TX; 11McMaster University, Hamilton, ON; 12University of Western Ontario, London, ON

88  A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL ULTRASOUND GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT PROSTATE CANCER AFTER EXTERNAL BEAM RADIOTHERAPY (NRG/RTOG 0526) Juanita Crook1, Peixin Zhang2, Thomas Pisansky3, Edouard Trabulsi4, Mahul Amin5, William Bice6, Gerard Morton7, Nadeem Pervez7, Eric Vigneault8, Jeff Michalski9, Charles Cattan9, Mack Roach11, David Beyer12, Peter Ross1113, Eric Horitz13, Viroon Donavanik15, Chistiana Care15, Howard Sandler15; 1University of British Columbia, Kelowna, BC; 2New Jersey Institute of Technology, Philadelphia, PA; 3University of Rochester, Rochester, MN; 4Thomas Jefferson University, Philadelphia, PA; 5Cedars-Sinai Medical Center, Los Angeles, CA; 6John Muir Health Systems, Walnut Creek, CA; 7University of Toronto, Toronto, ON; 8University of Calgary, Calgary, AB; 9Centre Hospitalier Universite de Quebec, Quebec, QC; 10Washington University, St Louis, MO; 11UCSF, San Francisco, CA; 12Cancer Center of Northern Arizona, Scottsdale, AZ; 13Emory University, Atlanta, GA; 14Fox Chase, Philadelphia, PA; 15Newark, DE
89 A PILOT STUDY OF SALVAGE HDR BRACHYTHERAPY IN PATIENTS WITH RECURRENT PROSTATE CANCER AFTER PRIMARY RADIATION: TOXICITY PROFILE AND OUTCOMES William Foster1, Eric Vigneault2, Marie-Claude Lavallée3, André-Guy Martin4; 1CHUQ Hotel-Dieu de Québec, Québec, QC; 2Université Laval, Québec, QC

90 THE USE OF CHEMOTHERAPY IN PLACE OF RADIOTHERAPY DOES NOT RESULT IN A LOWER INCIDENCE OF SECOND CANCERS IN PATIENTS WITH EARLY STAGE SEMINOMA: A POPULATION BASED STUDY IN BRITISH COLUMBIA Gaurav Bahl1, Rima Pathak1, Jenny Ko1, Michael Sia2, Christian Kollmannsberger2, Scott Tyldesley2; 1British Columbia Cancer Agency, Abbotsford, BC; 2British Columbia Cancer Agency, Vancouver, BC

91 RADIOTHERAPY QUALITY ASSURANCE OF CONCURRENT CHEMOTHERAPY IN PROCLAIM PHASE III TRIAL Anthony Brade1, Frederik Wenz2, Friederike Koppe3, Yolande Lievens4, Belen San Antonio5, Neill Iscoe6, Anwar Hossain7, Nadia Chouaki8, Suresh Senan9; 1Peel Regional Cancer Centre, Mississauga, ON; 2University Health Network, Toronto, ON; 3Institute Verbeeten, Tilburg, Netherlands; 4Ghent University Hospital, Ghent, Belgium; 5Madrid, Spain; 6Toronto, ON; 7Indianapolis, IN; 8Neuilly-sur-Seine, France; 9VU University Medical Center, Amsterdam, Netherlands

2:45-3:00 Keynote Toronto I
Introduction: Fabio Cury
Beyond Medicine – The Human Touch, Life of Professionals!
Shelly Dev

3:00-3:15 CLOSING REMARKS Toronto I
POSTER ABSTRACTS

93 ROLE OF MRI IN DETECTING LOCAL FAILURE FOLLOWING DEFINITIVE CHEMORADIATION IN LOCALLY ADVANCED CERVICAL CANCER
Pencilla Lang1, Jennifer Croke2, Magali Lecaivaler-Barousm2, Shira Felder2, Michael Milosevic2, Anthony Fyles2, Kathy Han2;
1University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON

94 CLINICAL APPLICATION OF THREE-DIMENSIONAL PRINTING FOR SURFACE HIGH-DOSE RATE BRACHYTHERAPY
Yizhou Zhao, Kathryn Moran, Mammo Yewondwossen, James Allan, Scott Clarke, Paul Joseph, James Robar Dalhousie University, Halifax, NS

95 CARDIAC SPARING RADIOTHERAPY USING CUSTOMIZED BREAST SHELL FOR LEFT SIDED BREAST CANCER PATIENTS
Khalifa Alkaabi1, Kunan Joseph1, Susan Chafe1, Zsolt Gabodi3, Keith Tankel1, Patricia Tai1, Sunita Ghosh2, Brad Warkentin1, Heather Warkentin1, Lee-Anne Polkosnik1, Kent Powell1, Johanna Jacobs1;
1University of Alberta, Edmonton, AB; 2University of Saskatchewan, Regina, SK

96 TRANSLATING RESEARCH INTO PRACTICE – EARLY RESULTS OF AN INSTITUTIONAL POLICY CHANGE FOR DEEP INSPIRATION BREATH HOLD (DIBH) IN RIGHT-SIDED BREAST CANCER PATIENTS
Jessica L Conway1, Karen Long2, Tien Phan2, Peter Craighead2, Leigh Conroy2, Wendy Smith2, Ivo A Olivotto1;
1Tom Baker Cancer Centre, Calgary, AB; 2University of Calgary, Calgary, AB

97 SUBVENTRICULAR ZONE DOSE AND OUTCOME IN A LARGE COHORT OF GLOBLASTOMA MULTIFORME TREATED WITH SURGERY AND CONCURRENT CHEMORADIOTHERAPY BETWEEN 2006 – 2012
Sonja Murchison1, Brad Wisky2, Stacey Grossman2, Brigit Jensen2, Dorothy Sayers2, Abraham Alexander2;
1British Columbia Cancer Agency Vancouver Centre, Vancouver, BC; 2British Columbia Cancer Agency Vancouver Island Centre, Victoria, BC

98 INSTITUTIONAL REVIEW OF GLIOMA TUMOURS TREATED WITH CHEMOTHERAPY: THE FIRST DESCRIPTION OF PCV-RELATED PSEUDOPROGRESSION
Ankur Sharma1, Oliver Bucher2, Michael Willcock1, M Nazir Khan1, Thelina Amaratunga1, Shaun Loewen1, Harvey Quon3, Marco Essig1, Marshall Pittz1;
1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB; 3University of Calgary, Calgary, AB

99 CHANGES IN APPARENT DIFFUSION COEFFICIENT (ADC) OF THE DOMINANT TUMOUR DURING DOSE-PAINTED RADIOTHERAPY AND HIGH DOSE RATE (HDR) BRACHYTHERAPY FOR PROSTATE CANCER
Sangjune Lee1, Warren Foltz2, Jenny Lee2, Tim Craig3, Alejandro Berini3, Peter Chung4, Cynthia Ménard4;
1University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON; 3University of Montreal Hospital (CHUM), Montreal, QC

100 SHOULD PTV MARGIN BE INCREASED IF ONE OR TWO PROSTATE SEEDS MIGRATE?
Faize AlShaﬁ1, K aden K ujm a p a 2, R yan R iv es 3, A rbind D u b e y 4, A m i t a v a C h o w d h u r y 1, A l dr ic h O n g 1, H a r v e y Q u o n 4, S h ah i da A h me d 1, B a si r B a s hi r 5, B o y d M c C u r d y 5, R a sh mi K ou l 1, 2; 1CancerCare Manitoba, Winnipeg, MB; 2University of Toronto, Toronto, ON; 3University of Manitoba, Winnipeg, MB; 4University of Calgary, Calgary, AB

101 TRANSITION TO PRACTICE: CREATION OF A TRANSITIONAL ROTATION FOR RADIATION ONCOLOGY RESIDENTS
H ann a h D a h n, K a re n W atts, L a r a B e s t, D a v id B owes; Dalhousie University, Halifax, NS

102 FORMAL AND INFORMAL MENTORSHIP IN AN ACADEMIC RADIATION ONCOLOGY DEPARTMENT: IMPACT, ATTITUDES AND FUTURE DIRECTIONS
Trisha Daigle-Maloney, David Bowes, Karen Watts; Dalhousie University, Halifax, NS

103 INTRODUCTION TO RADIATION ONCOLOGY ROTATION – SMOOTHING TRANSITION TO DISCIPLINE
Trisha Daigle-Maloney, David Bowes, Karen Watts; Dalhousie University, Halifax, NS

104 AN IN VIVO MODEL TO STUDY THE USE OF NANO PARTICLES AS A RADIosensitizer in RADIATION BEAMS GENERATED FROM A LOW Z TARGET
Michael Ha1, Olivia Piccolo2, Nicole Melong2, David Parsons1, Alexandre Delappel1, Olivier Tillement1, Ross Berbeco1, Jason Berman1, James Robar2;
1Dalhousie University, Halifax, NS; 2IWK Health Centre, Halifax, NS; 3Harvard Medical School, Boston, MA; 4Université de Lyon, Villeurbanne, France

105 IS CANCER OF ESOPHAGUS A SYSTEMIC DISEASE?
Xuanlu Qu, Aamer Mahmud; Queen’s University, Kingston, ON

106 NEOADJUVANT CHEMORADIATION VERSUS RADIATION ALONE IN LOCALLY ADVANCED COLON CANCER WITH A THREATENED MARGIN AND RESULTANT RD RESECTION RATES
Jason Ding, Marko Simunovic, Raimond Wong; McMaster University, Hamilton, ON

107 COMPARISON OF POST-RADIOTHERAPY PROSTATE SPECIFIC ANTIGEN DROP KINETICS BETWEEN EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY
D eepak D inakaran, M ax well Uhlich, M ichael W ang, Sunita G h osh, C a t a l i n a V asquez, J ohn L ewis, N awaid U sm a ni, A PCaRI Consortium; University of Alberta, Edmonton, AB

108 A PROSPECTIVE, PHASE I DOSE-ESCALATION TRIAL OF STEREOTACTIC ABLATIVE RADIOTHERAPY AS AN ALTERNATIVE TO CYTOTOXIC NPHRECTOMY FOR PRIMARY RENAL TUMOURS IN THE SETTING OF METASTATIC RENAL CELL CARCINOMA
Rohann Correa1, Andrew Warner1, Craig Johnson2, George Rodrigues, Belal Ahmed3, Alexander Louie1; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON
109 IMPACT OF ADIPOSE TISSUE DISTRIBUTION ON CANCER AGGRESSIVENESS AND POSITIVE MARGINS AFTER RADICAL PROSTATECTOMY David Tiberi1, Guila Delouya1, Sahir Bhatnagar2, Marolie Barkati1, Shanie Campeau1, Denis Rompotinos1, Daniel Taussky2; 1Université de Montréal, Montreal, QC; 2McGill University, Montreal, QC.

110 UROLOGY RESIDENT EXPOSURE TO RADIATION AND MEDICAL ONCOLOGY IS LIMITED Kevin Martell1, Amandeep Taggar2, Siraj Husain1, Michael Peacock3, Michael Sia1, Geoff Gotto2; 1University of Calgary, Calgary, AB; 2Memorial Sloan Kettering Cancer Centre, New York, NY; 3University of British Columbia, Vancouver, BC.

111 QUANTIFICATION OF CELL-FREE DNA IN BREAST CANCER PATIENTS RECEIVING ADJUVANT RADIOTHERAPY Sangjune Lee, Justin Burgener, Wei Xu, Cathy Han, Fei-Fei Liu, Scott Bratman; University of Toronto, Toronto, ON.

112 ADJUVANT RADIOTHERAPY ALONE VS CHEMORADIATION IN STAGE III PELVIC-CONFINED ENDOMETRIAL CANCER Reem Albeesh1, Joanne Alfieri, José João Mansure, Guy-Anne Turgeon, Lili Fu, Jocelyne Arseneau, Kris Jardon, Lucy Gilbert, Luis Souhami; McGill University, Montreal, QC.

113 PRIMARY RADIOTHERAPY FOR CERVIX CANCER: ARE RESULTS IMPROVING? Gaurav Bhattacharya, Najjaa Alyamani, Rajiv Samant, Choa E, Graham George Cook, Tien Le, Krystine Lupe; The University of Ottawa, Ottawa, ON.

114 ORGAN PRESERVATION WITH EXTERNAL BEAM RADIATION AND SYSTEMIC THERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED LARYNGEAL CANCER: AN INSTITUTIONAL EXPERIENCE Laura Callan1, Tina (Wanting) Zhang1, Tsu-Hui (Hubert) Law2, Chris O’Brien Lifehouse2, David Yeh3, Raksha Araslanova4, Eric Winquist5, Sara Kuruvilla6, James A Hammond6, Nancy Read6, David A Palma1, Anthony Nichols1, Varagur Venkatesan1; 1University of Western Ontario, London, ON; 2Sydney, NSW, Australia.

115 PROGNOSTIC FACTORS AFFECTING THE CLINICAL OUTCOME IN MALIGNANT PAROTID GLAND NEOPLASM Faiez AlShafa1, Andrew Cooke1, Dorian Muraniu2, Shrinvasis Rathod2, Richard Nason2, Ahmet Leylek2, Jim Butler2, Rashmi Kouf2; 1CancerCare Manitoba, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB.

116 TPF INDUCTION CHEMOTHERAPY FOR LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA (LA NPC) Stacey Davidson, David Palma, Suzanne Richter, Sara Kuruvilla, Varagur Venkatesan, Nancy Read, Anthony Nichols, Kevin Fung, Danielle MacNeil, John Yoo, Eric Winquist; University of Western Ontario, London, ON.

117 CORRELATING ACUTE DYSPHAGIA TO PTV SIZE IN HEAD AND NECK CANCER PATIENTS RECEIVING RADIOTHERAPY WITH IMRT Deepak Dinakaran1, Andrew Lim1, Robyn Banerjee2, Brock Debenham2; 1University of Alberta, Edmonton, AB; 2Tom Baker Cancer Centre, Calgary, AB; 3Cross Cancer Institute, Edmonton, AB.

118 THE MANAGEMENT OF LARYNGEAL CANCER IN MOROCCO: EXPERIENCE OF MOHAMMED VI UNIVERSITY HOSPITAL CENTER OF MARRAKESH Jamal Drissi, Marieme Affane, Abdelhamid Elomrani, Abdelaziz Raji, Hanane Rais, Najat Cherif IdriSSI El gnouni, Mouna Khouchani Cady Ayad University, Marrakesh, Morocco.

119 TREATMENT, TECHNOLOGY AND TIME-TRENDS IN THE MANAGEMENT OF LIMITED STAGE SMALL CELL LUNG CANCER Hanbo Chen1, Emma Ali2, Andrew Warner2, George Rodrigues2, Alexander Louie2; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON.

120 INSTITUTIONAL PRACTICES AND PREDICTORS OF SURVIVAL FOR LIMITED-STAGED SMALL CELL LUNG CANCER – A RETROSPECTIVE ANALYSIS Hanbo Chen1, Emma Ali1, Andrew Warner2, George Rodrigues2, Alexander Louie2; 1University of Western Ontario, London, ON; 2London Health Sciences Centre, London, ON.

121 SPINAL INVOLVEMENT IN MYELOMA: INCIDENCE, SURVIVAL AND IMPACT OF RADIOTHERAPY Ankur Sharma1, Derek Buudefeld2, Mykola Sackett2, Pascal Lambert2, Vikram Wadhwa3, RamI Kotb3, Naseer Ahmed3; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB; 3New York - Presbyterian, New York, NY.

122 AID “AWARENESS OF INCURABLE DISEASE” – ONE-PAGE QUESTIONNAIRE TO HELP PATIENTS AND DOCTORS Ziad Simon Fawaz, Marc David, Sergio Faria; McGill University Health Centre, Montreal, QC.

123 PROGNOSTICATION WITH FDG-PET IN ANAL CANAL CARCINOMA Adele Duimering1, Terence Riauka1, Alexander McEwan1, Sunita Ghosh1, Yugmeh Nijjar2, Johanna Jacobs3, Rebecca Reif3, Tirth Nijjar2, Diane Severin2, Keith Tankel1, Nawaid Usmani1, Alysa Fairchild1, Robert MacEwan1, Emmanuel Hudson1, Clarence Wong2, Daniel Schiller1, Karen Mulder1, Corinne Döll1, Kuriyan Joseph1; 1Cross Cancer Institute, Edmonton, AB; 2University of Calgary, Calgary, AB; 3University of Leuven, Leuven, Flanders, Belgium; 4Northern Alberta Institute of Technology, Edmonton, AB; 5University of Alberta, Edmonton, AB; 6Tom Baker Cancer Centre, Calgary, AB.

124 THE ROLE OF 18F-FLUOROCHOLINE (18F-FCH) PET IN PROSTATE CANCER IMAGING: AN UPDATED SYSTEMATIC REVIEW OF THE LITERATURE Tina Wanting Zhang, Irina Rachinsky, Gabriel Boldt, Michael Kovacs, Aaron Ward, Glenn Bauman; London Health Sciences Centre, London, ON.

125 IMPROVEMENTS IN QUALITY OF LIFE AS EARLY AS DAY 10 FOLLOWING RADIATION TREATMENT: A SECONDARY ANALYSIS OF THE NCIC CLINICAL TRIALS GROUP SYMPTOM CONTROL TRIAL SC.23 Rachel McDonald1, Srinivas Raman1, Keyue Ding1, Edward Chow1, Ralph M Meyer1, Abdenour Nabi1, Pierre Chabot1, Genevieve Coulombe1, Shahida Ahmed1, Joda Kuk1, Rashid Dar2, Aamer Mahmud10, Alysa Fairchild1, Carolyn F. Wilson4, Jackson SY Wu5, Kristopher Dennis6, Carlo DeAngelis1, Rebecca KS Wong1, Liting Zhu1, Michael Brundage1; 1University of Toronto, Toronto, ON.
AGE DIFFERENCES IN RESPONSE AND PATIENT REPORTED OUTCOMES: A SECONDARY ANALYSIS OF THE NCIC CTG SC.23 RANDOMIZED TRIAL
Selina Chow1, Srinivas Raman1, Keyue Ding2, Edward Chow1, Ralph M Meyer3, Abdenour Nadib4, Pierre Chabot5, Genevieve Coulombe4, Shahida Ahmed4, Joda Kuk6, Rashid Dar2, Aamer Mahmud7,10, Alysa Fairchild11, Carolyn F Wilson2, Jackson SY Wu12, Kristopher Dennis13, Carlo DeAngelis1, Rebecca KS Wong1, Liting Zhu2, Michael Brundage2; 1University of Toronto, Toronto, ON; 2University of Western Ontario, London, ON; 3University of Calgary, Calgary, AB; 4University of Ottawa, Ottawa, ON; 5McMaster University, Hamilton, ON; 6Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC; 7Hospital Maisonneuve-Rosemont, Montreal, QC; 8CHUM-Hopital Notre-Dame, Montreal, QC; 9CancerCare Manitoba, Winnipeg, MB; 10Grand River Regional Cancer Centre, Kitchener, ON; 11London Regional Cancer Program, London, ON; 12Cancer Centre of Southeastern Ontario, Kingston, ON; 13University of Toronto, Toronto, ON; 14The University of Chicago, Chicago, IL

GENDER DIFFERENCES IN PAIN AND PATIENT REPORTED OUTCOMES: A SECONDARY ANALYSIS OF THE NCIC CTG SC.20 RANDOMIZED TRIAL
Ronald Chow1, Srinivas Raman1, Bingshu E Chen2, Ralph M Meyer3, Yvette M van der Linden4, Daniel Roos5, William F Hartstell5, Peter Hoskin6, Jackson SY Wu6, Abdenour Nadib7, Caroline JA Tissing-Tan8, Bing Oei9, Scott Babington3, William F Demas10, Carolyn F Wilson11, Rebecca KS Wong12, Michael Brundage1, Liting Zhu1, Edward Chow1; 1University of Toronto, Toronto, ON; 2University of Western Ontario, London, ON; 3University of Calgary, Calgary, AB; 4Grand River Regional Cancer Centre, Kitchener, ON; 5London Regional Cancer Program, London, ON; 6Cancer Centre of Southeastern Ontario, Kingston, ON; 7University of Toronto, Toronto, ON; 8University of Ottawa, Ottawa, ON; 9CancerCentre of Southeastern Ontario, Kingston, ON; 10CancerCare Manitoba, Winnipeg, MB; 11Queen’s University, Kingston, ON; 12University of Toronto, Toronto, ON; 13McMaster University, Hamilton, ON; 14Leiden University Medical Centre, Leuwarden, Netherlands; 15University of Adelaide, Adelaide, Australia; 16Central DuPage Hospital Cancer Center, Warrenville, IL; 17Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom; 18University of Calgary, Calgary, AB; 19Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC; 20Institute for Radiation Oncology Arnhem, Arnhem, Netherlands; 21Dr Bernard Verbeetn Instituut, Tilburg, Netherlands; 22Christchurch Hospital, Christchurch, New Zealand; 23Northeast Ohio Medical University, Akron, OH

CLASSIFICATION OF PAINFUL BONE METASTASES AS MILD, MODERATE, OR SEVERE USING BOTH EORTC QLQ-C15-PAL AND EORTC QLQ-BM22
Rachel McDonald1, Srinivas Raman1, Keuye Ding2, Edward Chow1, Ralph Meyer3, Abdenour Nadib4, Pierre Chabot5, Shahida Ahmed5, Joda Kuk6, Rashid Dar2, Aamer Mahmud7, Alysa Fairchild11, Carolyn F Wilson11, Jackson SY Wu12, Kristopher Dennis13, Carlo DeAngelis1, Rebecca KS Wong1, Liting Zhu2, Genevieve Coulombe22, Michael Brundage2; 1University of Toronto, Toronto, ON; 2University of Western Ontario, London, ON; 3University of Calgary, Calgary, AB; 4University of Ottawa, Ottawa, ON; 5McMaster University, Hamilton, ON; 6Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC; 7Hospital Maisonneuve-Rosemont, Montreal, QC; 8CancerCare Manitoba, Winnipeg, MB; 9Grand River Regional Cancer Centre, Kitchener, ON; 10London Regional Cancer Program, London, ON; 11Cancer Centre of Southeastern Ontario, Kingston, ON; 12Cross Cancer Institute, Edmonton, AB; 13University of Ottawa, Ottawa, ON; 14Sunnybrook Odette Cancer Centre, Toronto, ON; 15CHUM-Hopital Notre-Dame, Montreal, QC
135  STANDARDIZATION OF ONCOLOGY RESIDENT HANDOVER NOTES IN ORDER TO IMPROVE PATIENT SAFETY  Mohamed Ahmed Abdi, Catherine deMetz; Queen’s University, Kingston, ON

136  COST EFFECTIVENESS ANALYSIS OF UTILIZING 3D PRINTER TECHNOLOGY TO CREATE BOLUS FOR RADIOTHERAPY: AN INSTITUTIONAL EXPERIENCE  Ankur Sharma, Arbind Dubey, David Sasaki, Daniel Rickey, Chad Harris, Jorge Alpuche, Sandra Iftody, Boyd McCurdy, Rashmi Koul; University of Manitoba, Winnipeg, MB

137  COMPASS: A PATIENT CENTRIC CARE IN THORACIC MALIGNANCY DISEASE SITE GROUP  Reem Alomran1, Dorian Murariu, Grace Musto, Carrie O’Coniff1, Jill Sutherland, Rashmi Koul1; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB

138  CANCER CARE ONTARIO’S COMMUNITIES OF PRACTICE: A SCOPING EVALUATION  Rachel Glucksman, Michelle Ang, Elizabeth Murray, Carina Srinivasan, Elizabeth Lockhart, Julie Gilbert, Eric Gutierrez, Padraig Wardle1; 1University of Toronto, Toronto, ON; 2Cancer Care Ontario, Toronto, ON

139  DIGITAL DISPLAYS IMPACT ON PATIENTS IN RADIATION THERAPY FLOOR  Faiez AlShafa, Jill Sutherland, Gina Kowalski, Michelle Bennett, Rashmi Koul; CancerCare Manitoba, Winnipeg, MB

140  PATIENT REPORTED OUTCOMES SUPPORT SYSTEM RESPONSIVENESS TO AREAS OF HIGH SYMPTOM  Reem Alomran1, Jill Sutherland2, Linda Watson1, Deb Bulych1, Rashmi Koul1; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB; 3Alberta Health Services, Calgary, AB; 4Saskatchewan Cancer Agency, Regina, SK

141  A CURRENT STATE RESEARCH ACTIVITY ASSESSMENT IN A MID SIZED RADIOTHERAPY DEPARTMENT  Faiez AlShafa, Jill Sutherland, Chris Zeller, Rashmi Koul; CancerCare Manitoba, Winnipeg, MB

142  UTILIZATION OF 3D PRINTING IN SURGICAL ONCOLOGY: AN INSTITUTIONAL REVIEW OF COST AND TIME EFFECTIVENESS  Ankur Sharma1, Arbind Dubey, Daniel Rickey, Tom Hayakawa, Alok Pathak1, Edward Buchef1, David Sasaki1, Chad Harris2, Boyd McCurdy, Rashmi Koul1; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB

143  ANALYSIS OF FIRST CASE SERIES IN THE WORLD OF SKIN CANCER PATIENTS WHERE LEAD SHIELDING FOR RADIATION THERAPY OF FACIAL SKIN CANCER WAS DESIGNED UTILIZING OPTICAL SCANNER AND 3D PRINTER TECHNOLOGY  Ankur Sharma1, Arbind Dubey1, Ahmet Leyké1, Daniel Rickey1, David Sasaki1, Chad Harris2, Boyd McCurdy1, Rashmi Koul1; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB

144  PRE-TREATMENT SUVMAX IS NOT CORRELATED WITH PRE-TREATMENT TUMOUR GROWTH RATE IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH STEREOTACTIC RADIATION THERAPY (SBRT)  Soha Atallah, Marc Gaudet, Robert MacRae, Peter Cross, Jason Pantarotto; University of Ottawa, Ottawa, ON

145  PERCEPTIONS AND TIME EFFECTIVENESS OF UTILIZING 3D PRINTER TECHNOLOGY TO CREATE RIGID BOLUS FOR RADIOTHERAPY  Ankur Sharma1, Arbind Dubey1, David Sasaki1, Daniel Rickey1, Philip McGeachy1, Chad Harris2, Jennifer Beaudry2, Joelle Brown2, Michele Rief2, Michael Smyth2, Sandra Iftody2, Boyd McCurdy1, Rashmi Koul1; 1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB

146  AUTOMATED ASSESSMENT OF NASOPHARYNX GTV CHANGE ON DAILY CONE BEAM CT  Ahmad Bushehri1, Biu Chan1, Olive Wong1, Jenny Lee1, Shao Hui Huang1, Andrew Bayley1, John Cho1, John Kim1, Jolie Ringash1, Brian O’Sullivan1, John Waldron1, Jean-Pierre Bissonnette1, Andrea McNiven1, BeiBei Zhang1, Andrew Hope1, Meredith Giuliani1, Scott Bratman1; 1University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON

147  VALUE OF MRI IN CONTOURING NON-SPINE BONE METASTASES FOR STEREOTACTIC BODY RADIATION THERAPY  Srinivas Raman1, Darby Erler2, Lee Chin3, Patrick Cheung4, William Chu4, Hans Chung5, Andrew Loblaw5, Ian Poon6, Joel Rubenstein7, Hany Soliman7, Arjun Saghafi7, Chia-Lin Tseng8; 1University of Toronto, Toronto, ON; 2Sunnybrook Odette Cancer Centre, Toronto, ON

148  CLINICAL OUTCOMES OF CONTEMPORARY NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING WHOLE BRAIN RADIOTHERAPY: CRYSTALLIZING THE QUARTZ OUTCOMES  Michael H Wang, Melissa Hwang, Diane Severin, Zsolt Gabos, Tirath Nijjar, Brock Debenham, Wilson Roa, Don Yee, Karen P Chu, Rufus Scrimger, Alysa Fairchild; Cross Cancer Institute, Edmonton, AB

149  A CONTAMINATED BRACHYTHERAPY IR-192 SOURCE FOUND DURING A ROUTINELY SOURCE EXCHANGE: OUR EXPERIENCE AND LESSONS LEARNED  Étienne Létourneau, Fabiola Valleejo Castañeda, Fadi Hobelal, Amélie Lauzon; Université de Montréal, Laval, QC

150  IS INTRAOPERATIVE REAL-TIME DOSIMETRY IN PROSTATE SEED BRACHYTHERAPY PREDICTIVE OF OUTCOME?  Daniel Taussky1, Levan Igibashian1, David Donath2, Dominic Béliveau-Nadeau1, Larouche Renée-X1, Yannick Hervieux1, Guila Deloyau1; 1Université de Montréal, Montréal, QC; 2Cité de la Santé Laval, Laval, QC

151  MULTI-MODALITY IMAGE REGISTRATION FOR COMBINED MRI/CT HDR PROSTATE BRACHYTHERAPY: THE CONCEPT OF THE IURETHRA  Marjory Jolicoeur1, Talar Derashodian2, Jurgen Last3, Georges Wakil, Maryse Mondat4; 1Hospital Charles LeMoyne CIHM, Montréal, QC; 2Université Sherbrooke, Longueuil, QC

152  V150 AND URETHRAL DMAX PREDICT RADIATION INDUCED PROSTATITIS  Talar Derashodian, Melissa Le, Maryse Mondat, George Wakil, Jurgen Last, Marjory Jolicoeur; Université Sherbrooke, Sherbrooke, QC
NO VOLUMETRIC PREPLAN: INSTITUTIONAL EXPERIENCE WITH AN INTRACAVITY/INTERSTITIAL MR-BASED CERVIX IMPLANT STRATEGY Deepak Dinakaran1, Ericka Wiebe2, Geetha Menon3, Michele Janoski2, Janet Zimmer2, Robert Pearcey2, Fleur Huang2, 1University of Alberta, Edmonton, AB; 2Cross Cancer Institute, Edmonton, AB

PERMANENT SEED BRACHYTHERAPY FOR LOW-RISK PROSTATE CANCER: LONG TERM OUTCOME AND URINARY TOXICITY Hamid Raziee1, Alejandro Berlin1, Peter Chung1, Haiyan Jiang1, Juanita Crook2, Charles Catton1; 1University of Alberta, Edmonton, AB; 2Cross Cancer Institute, Edmonton, AB

ACURA DOES DELAY FROM PROSTATE CANCER DIAGNOSIS TO TREATMENT WITH PERMANENT SEED IMPLANTATION INCREASE THE RISK OF DISEASE RECURRENCE IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER? Eric Vigneault1, Khaly Mbojdi1, Sindy Magnan1, Philippe Després2, Marie-Claude Lavallée2, Sylviane Aubin2, Luc Beaulieu2, William Foster2, Andre-Guy Martin2; 1CHUQ, Québec, QC; 2University of Laval, Quebec, QC

CASARIA THE RISK OF SECOND MALIGNANCIES AFTER SEED MIGRATION IN PROSTATE CANCER PATIENTS TREATED WITH I-125 FREE SEEDS BRACHYTHERAPY Eric Vigneault1, Kevin Martell2, Daniel Taussky3, Siraj Husain1, Guila Delouya1, Khaly Mbojdi1, Sindy Magnan1, Philippe Després2, Marie-Claude Lavallée2, Sylviane Aubin2, Luc Beaulieu2, William Foster2, Andre-Guy Martin2; 1CHUQ, Québec, QC; 2University of Laval, Quebec, QC

PROSTATE DOWNSIZING WITH DEGARELIX: RESULTS OF A PHASE II TRIAL Martin Korzeniowski1, Juanita Mary Crook2, David Bowes3, Miren Gasañaga1, Ana Ots1, Jim Rose2, Jasbir Jaswal3, Bowes Karsten4, Andreas Schindel2, Thea Stroop1, Martin D Chang5, Clement Ho5, Haojian He2, Guila Delouya2, Khaly Mbojdi2, Sindy Magnan2, Philippe Després2, Marie-Claude Lavallée2, Sylviane Aubin2, Luc Beaulieu2, William Foster2, Andre-Guy Martin2; 1CHUQ, Québec, QC; 2University of Laval, Quebec, QC; 3University of Alberta, Edmonton, AB; 4University of Alberta, Edmonton, AB; 5Columbia, Prince George, BC

STEROIDIC THERAPY FOR DUCTAL CARCINOMA IN SITU IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY, SURGERY AND RADIOTHERAPY Monali Swain, Shirin Namini, Abdulla Al-Rashdan, David McCready, Rachel Fleming, Naomi Miller, Manjula Maganti, Anne Koch, Kathy Han; Princess Margaret Cancer Centre, Toronto, ON

STEREOTACTIC RADIOSURGERY FOR EPIDURAL SPINAL CORD COMPRESSION FROM SPINAL METASTASES Melissa Azoulay1, Kiran Kumar2, Clement Ho3, Evan White2, Dyllan Fujimoto2, Iris Gibbs2, Sonya Aggarwal3, John R Adler4, Steven D Chang5, Steven Hancock5, Clara Choi5, Scott Softs5; 1McGill University Health Centre, Montreal, QC; 2University of British Columbia, Vancouver, BC; 3University of British Columbia, Prince George, BC

STEREOTACTIC RADIOSURGERY ALONE IN PATIENTS WITH ≥5 BRAIN METASTASES Laurence Masson-Côté, Elodie Hamel-Perreault, David Mathieu; Université de Sherbrooke, Sherbrooke, QC

IMPLEMENTATION OF REAL-TIME MR-GUIDED INTERSTITIAL BRACHYTHERAPY FOR GYNECOLOGICAL CANCER Kitty Chan, Anna Simonov, Anne Di Tomasso, Gerald O’Leary, Ana Lopez Filici, Alexandra Rink, Akbar Beiki-Ardakani, Jette Borg, Jennifer Croke, Anthony Fyles, Kathy Han, Michael Milosevic; Princess Margaret Cancer Centre, Toronto, ON

EXPLORING OLDER WOMEN’S PERCEPTIONS REGARDING THE NEW SENIOR WOMEN’S BREAST CANCER CLINIC (SWBCC) AT SUNNYBROOK ODETTE CANCER CENTRE (SOCC) Michael Tjong, Ines Menjak, Maureen Trudeau, Rajin Mehta, Frances Wright, Fiona McCullock, Janet Ellis, Damien Gallagher, Leslie Gibson, Bonnie Bristow, Katie Rice, Ewa Szumacher; University of Toronto, Toronto, ON

PREDICTORS OF OUTCOME AND PATTERNS OF RECURRENCE FOR HIGH RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY, SURGERY AND RADIATION Shirin Nezafat Namini, Monali Swain, Abdulla Al-Rashdan, David McCready, Rachel Fleming, Naomi Miller, Manjula Maganti, Anne Koch, Kathy Han; Princess Margaret Cancer Centre, Toronto, ON

PREDICTORS OF PATHOLOGICAL COMPLETE RESPONSE AND OUTCOME IN HER2 POSITIVE BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT SYSTEMIC THERAPY, SURGERY AND RADIOTHERAPY Monali Swain, Shirin Namini, Abdulla Al-Rashdan, Manjula Maganti, David McCready, Rachel Fleming, Naomi Miller, Kathy Han, Christine Anne Koch; Princess Margaret Cancer Centre, Toronto, ON

TWICE-DAILY RADIOTHERAPY FOR RECURRENT OR RESISTANT BREAST CANCER Jonathan Klein, Gregor Zarnota; University of Toronto, Toronto, ON

PRESCRIBING PRACTICES OF ENDOCRINE THERAPY FOR DUCTAL CARCINOMA IN SITU IN BRITISH COLUMBIA Ahsen Chaudhry1, Theodora Koulis2, Caroline Speers3, Robert Olson4; 1University of British Columbia, Vancouver, BC; 2University of British Columbia, Prince George, BC

IMPROVED CBCT IMAGE QUALITY - A METHOD TO INCREASE ACCURACY OF CBCT BASED VENTILATION MEASURES Kasper R Jensen, Uffe Bernchou, Olufed Hansen, Carsten Brink; University of Southern Denmark, Odense, Fyn, Denmark
167 DUAL-ENERGY COMPUTED TOMOGRAPHY (DECT) FOR PREDICTION OF LOCAL RECURRENTCE IN LARYNX AND HYPOPHARYNX SQUMOUS CELL CARCINOMA; Houda Bahig, Andréanne Lapointe, Louise Lambert, Stephane Bedwani, Edith Filion, David Roberge, Jacques de Guise, Laurent Letourneau-Guillon, Phuc-Felix Nguyen-Tan; CHUM, Montreal, QC

168 DOSIMETRIC ADVANTAGE IN USING VMAT FOR TREATMENT IN STAGE III LUNG CANCER Rashmi Koul, Keith Sutherland, Shaun Loewen, Naseer Ahmed, Bashir Bashir, Ahmet Leylek, Amit Chowdhury, Julian Kim, Arbind Dubey; CancerCare Manitoba, Winnipeg, MB

169 PROSPECTIVE DOSIMETRIC EVALUATION OF THREE RADIATION DELIVERY TECHNIQUES FOR SPINAL METASTASES Sonia Skamenei, Diana Shi, Lauren Herton, Monica Krishnan, Ron Shiloh, Laura Warren, Dana Apkon, Kristin Roper, Johann Brown, Yu-Hui Chen, Tracy Balboni; Dana-Farber/Brigham and Women's, Boston, MA; Harvard Medical School, Boston, MA

170 PATIENT-REPORTED OUTCOME USE IN ONCOLOGY: A SYSTEMATIC REVIEW OF THE IMPACT ON PATIENT-PROVIDER COMMUNICATION Linda Yang, Dominick Manhas, A Fuchsia Howard, Robert Olson; University of British Columbia, Vancouver, BC

171 FEASIBILITY AND IMPACT OF ELECTRONIC COLLECTION OF REPEAT PATIENT REPORTED ANXIETY, DEPRESSION, AND SUICIDAL IDEATION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS Robert Olson, Vincent Lapointe, Sarah Sample, Douglas Ozier, Heather Rennie, Gina Mackenzie, Fuchsia Howard, Erika Brown, Alan Nichol; British Columbia Cancer Agency, Prince George, BC; British Columbia Cancer Agency, Vancouver, BC; University of British Columbia, Vancouver, BC

172 CANCER DEATHS DUE TO LACK OF UNIVERSAL ACCESS TO RADIOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM Lucas Mendez, Gustavo Fernandes, Eduardo Weltman; Sunnybrook Health Sciences Centre, Toronto, ON; Hospital Sirio Libanês, Brasilia, Brazil; Hospital Israelita Albert Einstein and University of São Paulo, São Paulo, Brazil

173 INFORMATION NEEDS OF HEAD AND NECK CANCER PATIENTS UNDERGOING RADIATION THERAPY: A PATIENT SATISFACTION SURVEY Sarah Hamilton, Cecilia Kim, Ruth Dillon, Lumininta Nica, Eric Berthelet; British Columbia Cancer Agency, Vancouver, BC

174 IDENTIFYING BARRIERS TO ACCRUAL IN RADIATION ONCOLOGY RANDOMIZED TRIALS: INSIGHTS FROM A TRIAL OF STEREOTACTIC RADIATION FOR OLIGOMETASTATIC DISEASE Joanna Laba, Suresh Senan, Devin Schellenberg, Stephen Harwood, Liam Mulroy, Sashendra Senthin, Anand Swaminathan, Neil Kopel, Jason Pantarotto, Larry Pan, Andrew Pearce, Andrew Warner, Alexander Louie, David Palma; University of Western Ontario, London, ON; VU University Medical Centre, Amsterdam, Netherlands; British Columbia Cancer Agency, Surrey, BC; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Dalhousie University, Halifax, NS; The Alfred Hospital, Melbourne, Australia; McMaster University, Hamilton, ON; McGill University, Montreal, QC; University of Ottawa, Ottawa, ON; Prince Edward Island Cancer Treatment Centre, Charlottetown, PE; Northeast Cancer Centre, Sudbury, ON; London Health Sciences Centre, London, ON

175 HAZARDS AND INCIDENTS: DETECTION AND LEARNING IN RADIATION MEDICINE, A COMPARISON OF TWO EDUCATIONAL INTERVENTIONS Robert Thompson, Yilan Lu, Marc Potvin, Jordan Holmes, Lisa Di Prospero, Brian Keller, Ewa Szumacher, Brian Liszewski, Pamela Catton, Meredith Giuliani, Bethany Pitcher, Melanie Pintilie, Jean-Pierre Bissonnette; University of Toronto, Toronto, ON; Princess Margaret Cancer Centre, Toronto, ON; Michener Institute, Institute, Toronto, ON

176 IT ONLY TAKES A MINUTE: THE DEVELOPMENT & IMPLEMENTATION OF A PATIENT EXPERIENCE SURVEY IN RADIATION THERAPY Merrylee McGuffin, Fatima Hashmi, Nikolas Gregor, Brian Liszewski, Angela Turner, Ruby Bola, Laura D’Alimonte, Lisa DiProspero; Sunnybrook Health Sciences Centre, Toronto, ON

177 THE FEASIBILITY OF CREATING A CLINICALLY USEFUL PATIENT REPORTED LUNG QUESTIONNAIRE FOR A PROVINCIAL RADIOTHERAPY PROGRAM Corinne Thompson, Robert Olson, Erika Brown, Vincent Lapointe; Cross Cancer Institute, Kelowna, BC; British Columbia Cancer Agency, Prince George, BC; University of Alberta, Prince George, BC; Vancouver, BC

178 THE CAUSE AND EFFECT CONUNDRUM: NEAR MISSES IN RADIATION ONCOLOGY Brian Liszewski; Odette Cancer Centre, Toronto, ON

179 MOTIVATIONAL INTERVIEWING FOR SMOKING CESSATION IN ONCOLOGY PATIENTS Bonnie Bristow, Andreia Scalco, Lisa Di Prospero; Odette Cancer Centre, Toronto, ON

180 CANADIAN RADIATION ONCOLOGY NEEDS RELATED TO GERIATRIC ONCOLOGY AND TREATMENT OF OLDER ADULTS WITH CANCER: NATIONAL SURVEY Rachel Leifer, Bonnie Bristow, Martine Puts, Shabhir Aliabadi, Kingshan Cao, Barbara-Ann Millar, Meredith Giuliani, Tina Hsu, Maureen Trudeau, Rajin Mehta, Ines Menjik, Mireille Norris, Barbara Liu, Ewa Szumacher; Odette Cancer Centre, Toronto, ON; University of Toronto, Toronto, ON; Sunnybrook Health Sciences Centre, Toronto, ON; University of Ottawa, Ottawa, ON

181 STIMULATION OF CANCER CELL INVASIVENESS AND LUNG METASTASIS DEVELOPMENT IN A MOUSE MODEL OF TRIPLE NEGATIVE BREAST CANCER Benoit Paquette; Université de Sherbrooke, Sherbrooke, QC
182 EFFECT OF TREATMENT SEQUENCING ON TUMOUR RESPONSE TO COMBINED TREATMENT WITH ULTRASOUND-DRIVEN MICROBUBBLES AND RADIOTHERAPY Jonathan Klein, William Tran, Priscilla Lai, Aizza Al-Mahrouki, Anoja Giles, Gregory Czarnota; University of Toronto, Toronto, ON.

183 RETROSPECTIVE REVIEW OF PATIENTS DIAGNOSED WITH RECTAL CANCER TREATED AT THE WINDSOR REGIONAL CANCER CENTRE BETWEEN 2002 AND 2010 Paul Dolinak, Khalid Hirzimiz, Caroline Hamm, Maher El-Masri, Ming Pan, John Mathews, Tarek Efiki, Akmal Ghafoor, Sindu Kanjhekal, Amin Kay, Indras Yoldie, Rasna Gupta, Swati Kulkarni, Kenneth Schneider, Colvin Springer, Junaid Yousef; Schulich School of Medicine & Dentistry Windsor Campus, Windsor, ON.

184 EARLY OUTCOMES OF PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER TREATED WITH TRIMODALITY TREATMENTS Nhu-Tram Nguyen, Emilia Timotin, Crystal Hann, Ranjan K Sur; Juravinski Cancer Centre, Hamilton, ON.

185 1006 PROSTATE CANCER PATIENTS WITH ULTRA-HIGH PROSTATE-SPECIFIC ANTIGEN Patricia Tai1, Asim Amjad2, Rashmi Koli1, Arbind Dubey3, Nelson Leong2, Evgeny Sadikov4, Wojciech Dolata5, Edward Yu6, David Skarsgard7; 1Allan Blair Cancer Centre, Regina, SK; 2University Saskatchewan, Regina, SK; 3University Manitoba, Winnipeg, MB; 4University of Western Ontario, London, ON; 5University Alberta, Calgary, AB.

186 ESCALATION FOR PROSTATE STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): LATE OUTCOMES FROM TWO PROSPECTIVE CLINICAL TRIALS Andrew Loblaw1, Patrick Cheung2, Geordi Pang3, Alexandre Mamedov4, Laura D’Alimonte5, Andrea Deabreu6, Kristina Commissio7, Lying Zhang8, Harvey Quon9; 1University of Toronto, Toronto, ON; 2University of Wisconsin, Madison, WI.

187 ACURA STEREOTACTIC BODY RADIOTHERAPY (SBRT) BOOST TO MICc HIGH-DOSE RATE (HDR) BRACHYTHERAPY BOOST FOR INTERMEDIATE RISK PROSTATE CANCER: A PHASE 1 STUDY Patrick Cheung1, Motasem Al-Hanaqta1, William Chu1, Ananth Ravi1, Andrew Chiang2, Sunee Jain3, Hans Chung4, Danny Vesprini1, Gerard Morton5, Andrea Deabreu1, Alex Mamedov1, Lying Zhang6, Darby Erler1, D Andrew Loblaw1; 1Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON; 2Northeast Cancer Centre, Health Sciences North, Sudbury, ON; 3Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom; 4Macrostat Inc., Toronto, ON.

188 PROGNOSTIC FACTORS IN RADIUM-223 TREATMENT- AN EARLY CANADIAN SINGLE-CENTER EXPERIENCE Guila Delouya, Daniel Taussky, Jean-Paul Bahary, Samer Traboulsi, Fred Saad, Maroie Barkati; Université de Montréal, Montreal, QC.

189 TESTOSTERONE DECREASE AFTER PROSTATE RADIOTHERAPY WITHOUT ANDROGEN DEPRIVATION THERAPY: INCIDENCE AND IMPACT ON RECURRENCE IN CONTEMPORARY PATIENTS Maroie Barkati1, Raisa Pompe2, Pierre Karakiewicz3, Emanuele Zaffuto4, Julie Piotte2, Zhe Tian5, Sami-Ramzi Leyh-Bannurah1, Jonas Schifflmann6, Guila Delouya2, Carole Lambert7, Jean-Paul Bahary2, Marie-Claude Beauchemin1, Cynthia Ménard1, Markus Graefen7, Derya Tilki8, Fred Saad1, Daniel Taussky2; 1Centre Hospitalier de l’Université de Montréal, Montreal, QC; 2Academic Hospital Braunschweig, Braunschweig, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany.

190 WITHDRAWN

191 A COMBINATION OF TESTOSTERONE AND WHITE BLOOD COUNT AS PREDICTIVE FACTORS OF OVERALL SURVIVAL IN LOCALIZED PROSTATE CANCER Daniel Taussky1, Denis Soulères1, Laurent Azoulay2, Hui Yin3, Jean-Paul Bahary4, Houda Bahig1, Guila Delouya1; 1Université de Montréal, Montréal, QC; 2McGill University, Montreal, QC.

192 A PIONEER OFF-SITE INJECTION PROGRAM FOR ANDROGEN DEPRIVATION THERAPY OF PROSTATE CANCER Patricia Tai1, Asim Amjad2, Wojciech Dolata2, Miroslav Janecwicz2, Arbind Dubey3, Rashmi Koli1, Nelson Leong2, Edward Yu6, Evgeny Sadikov2; 1Allan Blair Cancer Centre, Regina, SK; 2University of Saskatchewan, Regina, SK; 3University Manitoba, Winnipeg, MB; 4University of Western Ontario, London, ON.

193 IMRT WITH IMAGE-GUIDED BRACHYTHERAPY IN NON-METASTATIC LOCALLY ADVANCED CERVICAL CANCER Asma Saidi, Israël Fortin, Marie-Claude Beauchemin, Suzanne Kazandjian, Maroie Barkati; Centre Hospitalier de l’Université de Montréal, Montréal, QC.

194 WITHDRAWN

195 WITHDRAWN

196 PREVALENCE, PROGNOSIS, AND TREATMENT IMPLICATIONS OF RETROPHARYNGEAL NODES IN UNKNOWN PRIMARY HEAD AND NECK CARCINOMA Ali Hosni, Gild Horowitz, Eugene Yu, Wei Xu, Michael Au, Peter Dixon, David Goldstein, Douglas Chepeha, Shao Hui Huang, Andrew Bayley, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Brian O’Sullivan, Jolie Ringash, John Waldron, Ivan Weinreb, John de Almeida, Scott Bratman; Princess Margaret Cancer Centre, Toronto, ON.
197 INVESTIGATION OF ACCELERATED RADIOTHERAPY AND IMAGE GUIDANCE ON LOCAL CONTROL IN T2NO GLOTTIC CANCER TREATED WITH PARTIAL LARYNGEAL IMRT Kathy Rock, Shao Hui Huang, Albert Tiong, Lin Lu, Wei Xu, Li Tong, Andrew Bayley, Scott V Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Jolie Ringash, Brian O’Sullivan, John Waldron; University of Toronto, Toronto, ON

198 IMPACT OF TUMOUR BURDEN ON BRAIN METASTASES IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CARCINOMA Armin Rahmani, Sandra Pineda, Ahmad Bushehri, Lisa W Le, Andrea Bezjak, John Cho, Meredith Giuliani, Alexander Sun, Andrew Hope; University of Toronto, Toronto, ON

199 A SINGLE INSTITUTION EXPERIENCE IN TREATING OCTOGENARIANS WITH PRIMARY OR METASTATIC LUNG CANCER WITH LUNG STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND TOXICITY Muhammad Faisal Jamaluddin, Wilson Roa, Alysa Fairchild, Rufus Scrimger, Brock Debenham, Diane Severin, Tirath Nijjar, Sandeep Singhal, Ben Burke, Adele Duimering, Michael Wang, Karen P Chu, Don Yee, Hongwei Liu, Shannah Murland, Zsolt Gabos; University of Alberta, Edmonton, AB

200 COLLECTING PATIENT REPORTED OUTCOME MEASURES (PROs) AND PROVIDING FOLLOW-UP TO PALLIATIVE CANCER PATIENTS THROUGH THE PROSPECTIVE OUTCOME AND SUPPORT INITIATIVE (POSI): ONCOLOGY NURSES PERSPECTIVES OF THE UTILITY AND EFFECT ON PATIENT CARE Domnick Manhas, Linda Yang, Fuchsia Howard, Robert Olson; University of British Columbia, Vancouver, BC

201 WITHDRAWN

202 THE OTTAWA HOSPITAL RAPID PALLIATIVE RADIATION THERAPY PROGRAM: AUDIT OF A 2 YEAR PILOT EXPERIENCE Clare McGrath1, Kelly Linden2, Julie Renaud2, Alain Haddad1, Marc Gaudet1, Jason Pantarotto1, kristopher Dennis1; 1University of Ottawa, Ottawa, ON; 2The Ottawa Hospital, Ottawa, ON

203 PALLIATIVE RADIATION THERAPY FOR INUIT PATIENTS FROM NUNAVUT: A 10-YEAR REVIEW Jessica Chan1, Kelly Linden1, Clare McGrath1, Julie Renaud1, Paula Doering2, William MacDonald3, Marc Gaudet1, Jason Pantarotto1, Timothy Asmis2, kristopher Dennis1; 1University of Ottawa, Ottawa, ON; 2The Ottawa Hospital, Ottawa, ON; 3Government of Nunavut, Iqaluit, NU

204 WHO STILL RECEIVES WHOLE BRAIN RADIOTHERAPY? Alysa Fairchild, Adele Duimering, Sunita Ghosh, David Ma, Paul Li, Karen P Chu, Wilson Roa, Tirath Nijjar, Samir Patel, Diane Severin, Fleur Huang, Rufus Scrimger, John Amanie, Don Yee, Brock Debenham, Brita Danielson; Cross Cancer Institute, Edmonton, AB

205 DEFINING THE RANGE OF STANDARD PRACTICE FOR FIELD PLACEMENT AND TARGET VOLUME DEFINITION FOR BONE METASTASES AT THE OTTAWA HOSPITAL: GROUNDWORK FOR EVALUATING SKILL COMPETENCY IN A CLINICAL SPECIALIST RADIATION THERAPIST Kelly Linden1, Clare McGrath1, Kristopher Dennis1; 1The Ottawa Hospital, Ottawa, ON; 2University of Ottawa, Ottawa, ON

206 RT STUDENTS’ KNOWLEDGE, ATTITUDES AND BELIEFS ABOUT PALLIATIVE AND END-OF-LIFE CARE Carina Feuz1, Tara Rosewall1, Susan Willis2; 1University of Toronto, Toronto, ON; 2Sheffield Hallam University, Sheffield, United Kingdom

207 A GOOD DEATH: A CANADIAN PERSPECTIVE Carina Feuz1, Lorraine Hulley2; 1University of Toronto, Toronto, ON; 2Niagara College, Welland, ON

208 AN ANALYSIS OF NATIONAL TRENDS IN THE MANAGEMENT OF PAIN FLARE FOLLOWING PALLIATIVE RADIOTHERAPY FOR BONE METASTASES Stephanie Peters1, C Suzanne Drodge3; 1Laurentian University, Sudbury, ON; 3Memorial University, St. John’s, NL

209 COMPARISON OF MANUALLY REPORTED VERSUS AUTOMATICALLY DETECTED DOSIMETRIC INCIDENTS John French, Alison Giddings; British Columbia Cancer Agency, Vancouver, BC

210 THE USE OF “BIG DATA” TO MEASURE EFFICIENCY IN RADIATION THERAPY DELIVERY John French, Jenny Soo, Luminuta Nica, Lorenz Yeung; British Columbia Cancer Agency, Vancouver, BC

211 ASSESSING TOBACCO-RELATED CANCER SURVIVAL AMONG INDIVIDUALS WITH PSYCHIATRIC DISORDERS IN BRITISH COLUMBIA Mary McLay1, Robert Olson2, Russ Callaghan3; 1University of British Columbia, Vancouver, BC; 2University of Northern British Columbia, Prince George, BC

212 THE POWER OF POLICY ON ACCESS TO RADIATION TREATMENT: A SCOPING REVIEW OF POLICY INTERVENTIONS IMPLEMENTED IN ONTARIO FROM 1980 TO 2016 Gunita Mitera, Craig C Earle, Jeffrey Hoch, Anand Swaminath, Michael Brundage, Mark J Dobrow; 1University of Toronto, Toronto, ON; 2Ontario Institute for Cancer Research, Toronto, ON; 3University of California at Davis, Davis, CA; 4McMaster University, Hamilton, ON; 5Queen’s University, Kingston, ON

213 THE UNRECOGNIZED BENEFITS THAT COMMUNITIES OF PRACTICE CAN PROVIDE TO A PROVINCIAL AGENCY Michelle Ang1, Elizabeth Murray2, Carina Simnieceanu1, Elizabeth Lockhart2, Eric Gutierrez2, Padraig Ward2; 1CancerCare Ontario, Toronto, ON; 2University of Toronto, Toronto, ON
214  
**ASSESSING POTENTIAL IMPROVEMENT IN POST RADIATION THERAPY COMPLETION NOTES FROM A FAMILY PHYSICIAN PERSPECTIVE**  
Alexa Dang1, Robert Olson2, Dan Horvat2, Tammy Klassen-Ross3;  
1University of British Columbia, Vancouver, BC;  
2Northern Health, Prince George, BC;  
3University of British Columbia, Prince George, BC

215  
**WAIT TIMES FOR ADJUVANT BREAST RADIOTHERAPY IN THE BRITISH COLUMBIA SOUTHERN INTERIOR**  
Benjamin Mou1, Sarah McGregor2, Francois Germain1, Siavash Atrchian1, Sarah Lucas1, Angela Lin1, Christopher Baliski1, Islam Mohamed1;  
1British Columbia Cancer Agency, Kelowna, BC;  
2University of British Columbia Okanagan Campus, Kelowna, BC

216  
**VOLUMETRIC PREPLANNING FOR INTRACAVITY/INTERSTITIAL CERVIX BRACHYTHERAPY: AT WHAT COST?**  
Fleur Huang1, Deepak Dinakaran2, Ericka Wiebe1, Wendy Read1, Leanne Kellogg1, Michele Janoski1, Robert Pearcey1, Geetha Menon1;  
1Cross Cancer Institute, Edmonton, AB;  
2University of Alberta, Edmonton, AB

217  
**QUALITY IMPROVEMENTS – OUTCOME OF ADVOCACY FOR BREAST HEALTH**  
Lee Ann Martin1, Frances Wong1, Rhonda Janzen2, Paul Oxley2, Peter Doris2;  
1British Columbia Cancer Agency, Surrey, BC;  
2Surrey Memorial Hospital, Surrey, BC

218  
**HEPATOCELLULAR CARCINOMA INCIDENCE IN PATIENTS WHO HAVE OBTAINED A SUSTAINED VIROLOGIC RESPONSE FOLLOWING ANTIVIRAL THERAPY FOR HEPATITIS C: SYSTEMATIC REVIEW AND META-ANALYSIS**  
Ali Hosni1, Tawnya Hansen2, John Sampalis3, Yuxin Tu4, Arlene Nugent5;  
1Princess Margaret Cancer Centre, Toronto, ON;  
2University of Toronto, Toronto, ON;  
3McGill University, Quebec, QC

219  
**ENHANCING VALUE OF QUALITY ASSURANCE ROUNDS IN IMPROVING RADIOTHERAPY MANAGEMENT: A RETROSPECTIVE ANALYSIS**  
Fawzi Abuhijla1, Abdelatif Almousa1, Issa Mohamad1, Ali Hosni1, Sondos Alkhhatib1, Anoud Alnsoory1, Wafa Asha2, Ramiz Abuhijilah1, Jamal Khader2;  
1Princess Margaret Cancer Centre, Toronto, ON;  
2King Hussein Cancer Center, Amman, Jordan

220  
**RADIATION INCIDENT SAFETY COMMITTEE: IMPROVING QUALITY AND SAFETY WITHIN RADIATION TREATMENT**  
Carina Simnieceanu1, Eric Gutierrez2, Elizabeth Murray1, Michelle Ang1, Elizabeth Lockhart1, Gaylene Medlam1, Brian Liszewski3, Jordan Hunt1, Spencer Ross4, Erika Brown5, Padraig Ward6, Crystal Angers7;  
1CancerCare Ontario, Toronto, ON;  
2Peel Regional Cancer Centre, Toronto, ON;  
3Odette Cancer Centre, Toronto, ON;  
4CIHI, Ottawa, ON;  
5CPQR, Red Deer, AB;  
6University of Toronto, Toronto, ON

221  
**REGISTRATION WITH CONE BEAM CT USING SOFT TISSUE VERSUS FIDUCIAL MARKERS IN RADIOTHERAPY OF THE PROSTATE**  
Daegan Sr1, Ranjini Tolakanahalli1, Kristina Ritchie2, Kara Grant2, Diane D’Alessandro2, Ralph Strohschein2, Kimmen Quan1, Theos Tsakaridis3, Abhirami Hallock4;  
1McMaster University, Hamilton, ON;  
2Walker Family Cancer Centre, St. Catharines, ON;  
3University of Alberta, Edmonton, AB;  
4Dalhousie University, Halifax, NS

222  
**LINEAR ACCELERATOR BASED TOTAL MARROW IRRADIATION: DESCRIPTION OF TECHNIQUE AND INITIAL CLINICAL EXPERIENCE**  
Liam Mulroy1, Krista Chytlyk-Praznik1, Amanda Cherpak2, Jason Schella2, Thalat Monajemi2, Derek Wilke2, Carol-Anne Davis2, Jennifer DeGioibbi2, Allan Day3;  
1QEII Health Sciences Centre, Halifax, NS;  
2Dalhousie University, Halifax, NS

223  
**SAFETY OF LEFT VENTRICULAR ASSIST DEVICE ON A PATIENT WITH REPEATED HIGH DOSE RADIOTHERAPY TREATMENT: A CASE REPORT AND REVIEW OF THE LITERATURE**  
Muhammad Faisal Jamaluddin, Zsolt Gabos;  
University of Alberta, Edmonton, AB

224  
**CREATION OF A QUALITY DISPLAY TO INCREASE PATIENT ENGAGEMENT IN RADIATION ONCOLOGY DEPARTMENTS IN THE MARITIME PROVINCES**  
Lisa Peters1, David Bowes2, Laura Steeves3 Lisa Sinclair1, Meagan Darling1, Amanda Cherpak2, Lara Best2, Jill Trask2, Tracy Day2, Stephanie Freire3, Kathryn Moran3;  
1Dalhousie University, Sydney, NS, Canada;  
2Dalhousie University, Halifax, NS, Canada;  
3Dalhousie University, Saint John, NB, Canada;  
4Dalhousie University, Charlottetown, PE

225  
**A STUDY OF THE FEASIBILITY OF RADIATION THERAPIST-LED CONE BEAM COMPUTED TOMOGRAPHY MATCHING FOR LUNG STEREOCYSTIC BODY RADIOTHERAPY**  
Cecilia Kim1, Jenny Soo1, Robynn Ferris2, Rosanna Yeung2, Mitchell Liu2;  
1British Columbia Cancer Agency, Vancouver, BC;  
2University of Washington Medical Center, Seattle, WA;  
3University of British Columbia, Vancouver, BC

226  
**THE IMPACT OF CORRECTING FOR TRANSLATIONAL AND ROTATIONAL ERRORS USING THE HEXAPOD IN HEAD AND NECK STEREOCYSTIC BODY RADIATION THERAPY PATIENTS**  
Amanpreet Dhillon, Darby Erler, Ian Poon, Justin Lee, Danny Enepekides, Kevin Higgins, Lee Chin, Irene Karam;  
University of Toronto, Toronto, ON

227  
**DOSE EVALUATION SCRIPTING TO IMPROVE PLANNING QUALITY FOR GU VMAT TREATMENTS**  
Michael Lamey1, Grace Zeng2, Yongjin Wang2, Jasper Yuen2, Julie Murphy2;  
1Credit Valley Hospital, Mississauga, ON;  
2University of Toronto, Toronto, ON
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>228</td>
<td>A TREATMENT PLANNING STUDY OF VOLUMETRIC MODULATED ARC THERAPY FOR SAME-DAY PLANNING AND TREATMENT OF VERTEBRAL BONE METASTASES WITHIN A RAPID-ACCESS PALLIATIVE RADIATION THERAPY PROGRAM</td>
<td>Kelly Linden, Robert Zohr, Elsayed Ali, Julie Renaud, Miller MacPherson, Clare McGrath, Kristopher Dennis</td>
<td>1The Ottawa Hospital, Ottawa, ON; 2Carleton University, Ottawa, ON; 3University of Ottawa, Ottawa, ON</td>
</tr>
<tr>
<td>229</td>
<td>SABR FOR ULTRA-CENTRAL LUNG TUMOURS: ASSESSMENT OF TRADE-OFFS BETWEEN TARGET COVERAGE VERSUS SPARING OF CRITICAL STRUCTURES</td>
<td>Joanna Laba, Patrick Granton, Abigail Erickson, Barbara Millman, David Palma, Alexander Louie</td>
<td>1University of Western Ontario, London, ON; 2Erasmus MC, Rotterdam, Netherlands; 3London Health Sciences Centre, London, ON</td>
</tr>
<tr>
<td>230</td>
<td>COMPARISON OF DIFFERENT ADAPTIVE STRATEGIES FOR BLADDER CANCER RADIOTHERAPY USING DEFORMABLE DOSE ACCUMULATION</td>
<td>Aravindhan Sundaramurthy, Vickie Kong, Joelle Helou, Tara Rosewall, Tim Craig, Robert Bristow, Alejandro Berlin, Peter Chung</td>
<td>1Princess Margaret Cancer Centre, Toronto, ON</td>
</tr>
<tr>
<td>231</td>
<td>INTER-OBSERVER VARIABILITY IN STRUCTURE DELINEATION OF ORGANS AT RISK ON CONE BEAM CT USING RAYSTATION TPS V4.5.2</td>
<td>Olive Wong, Andrea McNiven, Biu Chan, Jenny Lee, Joanne Moseley, Cijian Ren, Scott Bratman, Andrew Hope, Jean-Pierre Bissonnette, John Waldron, Beibei Zhang, Meredith Giuliani, Princess Margaret Cancer Centre, Toronto, ON</td>
<td></td>
</tr>
<tr>
<td>232</td>
<td>IMPROVING THE QUALITY OF ON-CALL RADIOTHERAPY SERVICES</td>
<td>Julie Renaud, Jason Pantarotto, Gregory Fox, Robert Zohr, Daniel La Russa, Katie Lekx-Toniolo, Cathy Rose, Miller MacPherson</td>
<td>The Ottawa Hospital, Ottawa, ON</td>
</tr>
<tr>
<td>233</td>
<td>ANALYSIS OF MARGIN SCHEMA FOR NASOPHARYNGEAL CARCINOMA USING CLINICAL IMAGE GUIDED RADIATION THERAPY PROCESS AND DOSE ACCUMULATION</td>
<td>Joanna Javor, BeiBei Zhang, Olive Wong, Jenny Lee, Joanne Moseley, Jean-Pierre Bissonnette, Andrew Hope, Scott Bratman, John Waldron, Meredith Giuliani, Andrea McNiven, Princess Margaret Cancer Centre, Toronto, ON</td>
<td></td>
</tr>
<tr>
<td>234</td>
<td>RETROSPECTIVE STUDY ON SETUP ERRORS USING VOLUMETRIC IMAGING FOR SPINE SBRT PATIENTS</td>
<td>Michael Abdalmassih, Sankar Venkataraman, James Butler, Dorian Muraru, Arbind Dubey</td>
<td>1University of Manitoba, Winnipeg, MB; 2CancerCare Manitoba, Winnipeg, MB</td>
</tr>
<tr>
<td>235</td>
<td>STEREOTACTIC BODY RADIATION THERAPY FOR NON-SPINE BONE METASTASES: A SINGLE INSTITUTION’S EXPERIENCE</td>
<td>Darby Erler, Drew Brotherston, Arjun Sahgal, Patrick Cheung, William Chu, Hany Soliman, D Andrew Loblaw, Hans Chung, Edward Chow, Ian Poon</td>
<td>University of Toronto, Toronto, ON</td>
</tr>
<tr>
<td>236</td>
<td>ACURA CULTURAL ADAPTATION AND VALIDATION OF THE CHINESE VERSION OF EPIC</td>
<td>Tsz Kin Bernard Lee, Darren Poon, Anthony Ng, Terence Ho, Savitri Singh-Carlson, Michel Joffres, Gurpreet Oshan, Jagbir Kohli, Winkle Kwan</td>
<td>1British Columbia Cancer Agency, Abbotsford, BC; 2The Chinese University of Hong Kong, Hong Kong; 3California State University Monterey Bay, Marina, CA; 4Simon Fraser University, Burnaby, BC; 5University of British Columbia, Vancouver, BC; 6British Columbia Cancer Agency, Surrey, BC</td>
</tr>
<tr>
<td>237</td>
<td>EVIDENCE OR TRADITION? A CANADIAN REVIEW OF THE MANAGEMENT OF RADIATION INDUCED SKIN REACTIONS</td>
<td>Amanda Bolderton, Rachel Harris, Angela Cashell, Maurene McQuestion, Michele Cardoso, Clare Summers</td>
<td>1University of British Columbia, Surrey, BC; 2London, United Kingdom; 3University of Toronto, Toronto, ON; 4McMaster University, Hamilton, ON; 5Halifax, NS</td>
</tr>
<tr>
<td>238</td>
<td>PROGNOSTIC FACTORS FOR PERSISTENT OR LATE RADIATION SIDE EFFECTS IN BREAST CANCER PATIENTS - CLINICAL IMPACT FOR SURVIVORS</td>
<td>Fatemeh Fekrmandi, Tony Panzarella, Robert Dinniwell, Wilfred Levin</td>
<td>1University of Toronto, Toronto, ON; 2University of Western Ontario, London, ON</td>
</tr>
<tr>
<td>239</td>
<td>FEASIBILITY OF IMPLEMENTING A WEB-BASED PATIENT FOLLOW-UP PLATFORM INTO THE BRITISH COLUMBIA CANCER AGENCY FOR IMPROVING QUALITY OF LIFE CARE AND RESEARCH</td>
<td>Francois Bachand, Bhavan Panghal, Sara Taylor, Rasika Rajapakse</td>
<td>1British Columbia Cancer Agency, Kelowna, BC; 2University of British Columbia, Kelowna, BC</td>
</tr>
<tr>
<td>240</td>
<td>POST-TREATMENT VERIFICATION OF ITV MARGINS USING FOUR DIMENSIONAL CBCT</td>
<td>Niranjan Venugopal, Vijayananda Kundapur</td>
<td>University of Saskatchewan, Saskatoon, SK</td>
</tr>
<tr>
<td>241</td>
<td>THE ROLE OF CBCT AS PART OF A DAILY IMAGE GUIDED RADIOTHERAPY IN PROSTATE CANCER PATIENTS REQUIRING POSTOPERATIVE TREATMENT</td>
<td>Saba Elakshar, Tamim Niazi, Boris Bahoric, Nada Tomic, Frank Bladou, Joseph Papayanatos</td>
<td>McGill University, Montreal, QC</td>
</tr>
</tbody>
</table>
WELCOME TO CARO 2017

CARO2017  n IMPROVING CARE THROUGH EDUCATION, ADVOCACY, QUALITY OF LIFE AND BEYOND

2017 TORONTO, ONTARIO, CANADA

DR PAMELA CATTON MEMORIAL RUN/WALK FOR CROF

Saturday, September 16, 2017
Meet at the University Avenue Lobby door at 7:00am.
LOCAL AREA MAP AND CROF 5K RUN ROUTE
SAVE THE DATE
September 12-15, 2018

CARO-COMP
Joint Scientific Meeting 2018
Montreal, QC